Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15301728,Tmax,"In the homo EMs and the PMs groups, the main kinetic parameters were as follows: Tmax (2.44+/-0.85) and (2.33+/-0.94) h, Cmax(1.10+/-0.34) and (1.73+/-0.56) mg/L, Cl/F (16.55+/-0.38) and (3.58+/-1) L/h, T1/2ke (1.96+/-0.51) and (4.21+/-0.53) h, AUC were (3.23+/-0.08) and (11.05+/-0.23) mg.L(-1).",Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301728/),h,2.44,227,DB00448,Lansoprazole
,15301728,Tmax,"In the homo EMs and the PMs groups, the main kinetic parameters were as follows: Tmax (2.44+/-0.85) and (2.33+/-0.94) h, Cmax(1.10+/-0.34) and (1.73+/-0.56) mg/L, Cl/F (16.55+/-0.38) and (3.58+/-1) L/h, T1/2ke (1.96+/-0.51) and (4.21+/-0.53) h, AUC were (3.23+/-0.08) and (11.05+/-0.23) mg.L(-1).",Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301728/),h,2.33,228,DB00448,Lansoprazole
,15301728,Cmax,"In the homo EMs and the PMs groups, the main kinetic parameters were as follows: Tmax (2.44+/-0.85) and (2.33+/-0.94) h, Cmax(1.10+/-0.34) and (1.73+/-0.56) mg/L, Cl/F (16.55+/-0.38) and (3.58+/-1) L/h, T1/2ke (1.96+/-0.51) and (4.21+/-0.53) h, AUC were (3.23+/-0.08) and (11.05+/-0.23) mg.L(-1).",Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301728/),[mg] / [l],1.10,229,DB00448,Lansoprazole
,15301728,Cmax,"In the homo EMs and the PMs groups, the main kinetic parameters were as follows: Tmax (2.44+/-0.85) and (2.33+/-0.94) h, Cmax(1.10+/-0.34) and (1.73+/-0.56) mg/L, Cl/F (16.55+/-0.38) and (3.58+/-1) L/h, T1/2ke (1.96+/-0.51) and (4.21+/-0.53) h, AUC were (3.23+/-0.08) and (11.05+/-0.23) mg.L(-1).",Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301728/),[mg] / [l],1.73,230,DB00448,Lansoprazole
,15301728,Cl/F,"In the homo EMs and the PMs groups, the main kinetic parameters were as follows: Tmax (2.44+/-0.85) and (2.33+/-0.94) h, Cmax(1.10+/-0.34) and (1.73+/-0.56) mg/L, Cl/F (16.55+/-0.38) and (3.58+/-1) L/h, T1/2ke (1.96+/-0.51) and (4.21+/-0.53) h, AUC were (3.23+/-0.08) and (11.05+/-0.23) mg.L(-1).",Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301728/),[l] / [h],16.55,231,DB00448,Lansoprazole
,15301728,Cl/F,"In the homo EMs and the PMs groups, the main kinetic parameters were as follows: Tmax (2.44+/-0.85) and (2.33+/-0.94) h, Cmax(1.10+/-0.34) and (1.73+/-0.56) mg/L, Cl/F (16.55+/-0.38) and (3.58+/-1) L/h, T1/2ke (1.96+/-0.51) and (4.21+/-0.53) h, AUC were (3.23+/-0.08) and (11.05+/-0.23) mg.L(-1).",Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301728/),[l] / [h],3.58,232,DB00448,Lansoprazole
,15301728,T1/2ke,"In the homo EMs and the PMs groups, the main kinetic parameters were as follows: Tmax (2.44+/-0.85) and (2.33+/-0.94) h, Cmax(1.10+/-0.34) and (1.73+/-0.56) mg/L, Cl/F (16.55+/-0.38) and (3.58+/-1) L/h, T1/2ke (1.96+/-0.51) and (4.21+/-0.53) h, AUC were (3.23+/-0.08) and (11.05+/-0.23) mg.L(-1).",Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301728/),h,1.96,233,DB00448,Lansoprazole
,15301728,T1/2ke,"In the homo EMs and the PMs groups, the main kinetic parameters were as follows: Tmax (2.44+/-0.85) and (2.33+/-0.94) h, Cmax(1.10+/-0.34) and (1.73+/-0.56) mg/L, Cl/F (16.55+/-0.38) and (3.58+/-1) L/h, T1/2ke (1.96+/-0.51) and (4.21+/-0.53) h, AUC were (3.23+/-0.08) and (11.05+/-0.23) mg.L(-1).",Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301728/),h,4.21,234,DB00448,Lansoprazole
,15301728,AUC,"In the homo EMs and the PMs groups, the main kinetic parameters were as follows: Tmax (2.44+/-0.85) and (2.33+/-0.94) h, Cmax(1.10+/-0.34) and (1.73+/-0.56) mg/L, Cl/F (16.55+/-0.38) and (3.58+/-1) L/h, T1/2ke (1.96+/-0.51) and (4.21+/-0.53) h, AUC were (3.23+/-0.08) and (11.05+/-0.23) mg.L(-1).",Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301728/),[mg] / [l],3.23,235,DB00448,Lansoprazole
,15301728,AUC,"In the homo EMs and the PMs groups, the main kinetic parameters were as follows: Tmax (2.44+/-0.85) and (2.33+/-0.94) h, Cmax(1.10+/-0.34) and (1.73+/-0.56) mg/L, Cl/F (16.55+/-0.38) and (3.58+/-1) L/h, T1/2ke (1.96+/-0.51) and (4.21+/-0.53) h, AUC were (3.23+/-0.08) and (11.05+/-0.23) mg.L(-1).",Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301728/),[mg] / [l],11.05,236,DB00448,Lansoprazole
,31338800,half-life (t½),"The half-life (t½) and clearance (CL) of dexlansoprazole were 1.76-2.06 h and 4.52-5.40 L/h, respectively, while the t½ and CL of S-lansoprazole were 0.87-1.02 h and 34.66-35.98 L/h, respectively.",Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31338800/),h,1.76-2.06,4176,DB00448,Lansoprazole
,31338800,clearance (CL),"The half-life (t½) and clearance (CL) of dexlansoprazole were 1.76-2.06 h and 4.52-5.40 L/h, respectively, while the t½ and CL of S-lansoprazole were 0.87-1.02 h and 34.66-35.98 L/h, respectively.",Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31338800/),[l] / [h],4.52-5.40,4177,DB00448,Lansoprazole
,31338800,t½,"The half-life (t½) and clearance (CL) of dexlansoprazole were 1.76-2.06 h and 4.52-5.40 L/h, respectively, while the t½ and CL of S-lansoprazole were 0.87-1.02 h and 34.66-35.98 L/h, respectively.",Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31338800/),h,0.87-1.02,4178,DB00448,Lansoprazole
,31338800,CL,"The half-life (t½) and clearance (CL) of dexlansoprazole were 1.76-2.06 h and 4.52-5.40 L/h, respectively, while the t½ and CL of S-lansoprazole were 0.87-1.02 h and 34.66-35.98 L/h, respectively.",Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31338800/),[l] / [h],34.66-35.98,4179,DB00448,Lansoprazole
≥,31338800,TpH,"Zero to 24 h after q12h multiple dosing, median and mean intragastric pH, percentage of time with the intragastric pH above 4.0 [TpH ≥ 4.0(%)] and percentage of time with the intragastric pH above 6.0 [TpH ≥ 6.0(%)] in the dexlansoprazole 15 mg q12h group were 6.07 ± 0.61, 5.70 ± 0.76, 83.58 ± 12.34, and 53.70 ± 17.06, respectively, which was similar to the lansoprazole 30 mg q12h group, i.e. 6.15 ± 0.62, 5.88 ± 0.67, 87.26 ± 12.08 and 57.00 ± 16.35, respectively.",Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31338800/),%,4.0,4180,DB00448,Lansoprazole
≥,31338800,TpH,"Zero to 24 h after q12h multiple dosing, median and mean intragastric pH, percentage of time with the intragastric pH above 4.0 [TpH ≥ 4.0(%)] and percentage of time with the intragastric pH above 6.0 [TpH ≥ 6.0(%)] in the dexlansoprazole 15 mg q12h group were 6.07 ± 0.61, 5.70 ± 0.76, 83.58 ± 12.34, and 53.70 ± 17.06, respectively, which was similar to the lansoprazole 30 mg q12h group, i.e. 6.15 ± 0.62, 5.88 ± 0.67, 87.26 ± 12.08 and 57.00 ± 16.35, respectively.",Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31338800/),%,6.0,4181,DB00448,Lansoprazole
,31338800,TpH,"Zero to 24 h after q12h multiple dosing, median and mean intragastric pH, percentage of time with the intragastric pH above 4.0 [TpH ≥ 4.0(%)] and percentage of time with the intragastric pH above 6.0 [TpH ≥ 6.0(%)] in the dexlansoprazole 15 mg q12h group were 6.07 ± 0.61, 5.70 ± 0.76, 83.58 ± 12.34, and 53.70 ± 17.06, respectively, which was similar to the lansoprazole 30 mg q12h group, i.e. 6.15 ± 0.62, 5.88 ± 0.67, 87.26 ± 12.08 and 57.00 ± 16.35, respectively.",Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31338800/),%,53.70,4182,DB00448,Lansoprazole
,31338800,TpH,"Zero to 24 h after q12h multiple dosing, median and mean intragastric pH, percentage of time with the intragastric pH above 4.0 [TpH ≥ 4.0(%)] and percentage of time with the intragastric pH above 6.0 [TpH ≥ 6.0(%)] in the dexlansoprazole 15 mg q12h group were 6.07 ± 0.61, 5.70 ± 0.76, 83.58 ± 12.34, and 53.70 ± 17.06, respectively, which was similar to the lansoprazole 30 mg q12h group, i.e. 6.15 ± 0.62, 5.88 ± 0.67, 87.26 ± 12.08 and 57.00 ± 16.35, respectively.",Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31338800/),%,6.15,4183,DB00448,Lansoprazole
,31338800,TpH,"Zero to 24 h after q12h multiple dosing, median and mean intragastric pH, percentage of time with the intragastric pH above 4.0 [TpH ≥ 4.0(%)] and percentage of time with the intragastric pH above 6.0 [TpH ≥ 6.0(%)] in the dexlansoprazole 15 mg q12h group were 6.07 ± 0.61, 5.70 ± 0.76, 83.58 ± 12.34, and 53.70 ± 17.06, respectively, which was similar to the lansoprazole 30 mg q12h group, i.e. 6.15 ± 0.62, 5.88 ± 0.67, 87.26 ± 12.08 and 57.00 ± 16.35, respectively.",Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31338800/),%,5.88,4184,DB00448,Lansoprazole
,31338800,TpH,"Zero to 24 h after q12h multiple dosing, median and mean intragastric pH, percentage of time with the intragastric pH above 4.0 [TpH ≥ 4.0(%)] and percentage of time with the intragastric pH above 6.0 [TpH ≥ 6.0(%)] in the dexlansoprazole 15 mg q12h group were 6.07 ± 0.61, 5.70 ± 0.76, 83.58 ± 12.34, and 53.70 ± 17.06, respectively, which was similar to the lansoprazole 30 mg q12h group, i.e. 6.15 ± 0.62, 5.88 ± 0.67, 87.26 ± 12.08 and 57.00 ± 16.35, respectively.",Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31338800/),%,87.26,4185,DB00448,Lansoprazole
,31338800,TpH,"Zero to 24 h after q12h multiple dosing, median and mean intragastric pH, percentage of time with the intragastric pH above 4.0 [TpH ≥ 4.0(%)] and percentage of time with the intragastric pH above 6.0 [TpH ≥ 6.0(%)] in the dexlansoprazole 15 mg q12h group were 6.07 ± 0.61, 5.70 ± 0.76, 83.58 ± 12.34, and 53.70 ± 17.06, respectively, which was similar to the lansoprazole 30 mg q12h group, i.e. 6.15 ± 0.62, 5.88 ± 0.67, 87.26 ± 12.08 and 57.00 ± 16.35, respectively.",Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31338800/),%,57.00,4186,DB00448,Lansoprazole
,7587960,total body clearance,Elimination was rapid with total body clearance of 57.6 ml/min/kg for OPZ and 58.6 ml/min/kg for LPZ.,"Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587960/),[ml] / [kg·min],57.6,5162,DB00448,Lansoprazole
,7587960,total body clearance,Elimination was rapid with total body clearance of 57.6 ml/min/kg for OPZ and 58.6 ml/min/kg for LPZ.,"Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587960/),[ml] / [kg·min],58.6,5163,DB00448,Lansoprazole
,7587960,volumes of distribution at steady-state,"The volumes of distribution at steady-state were 0.66 liter/kg for OPZ and 1.04 liter/kg for LPZ, and the plasma unbound fractions were 0.105 and 0.069.","Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587960/),[l] / [kg],0.66,5164,DB00448,Lansoprazole
,7587960,volumes of distribution at steady-state,"The volumes of distribution at steady-state were 0.66 liter/kg for OPZ and 1.04 liter/kg for LPZ, and the plasma unbound fractions were 0.105 and 0.069.","Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587960/),[l] / [kg],1.04,5165,DB00448,Lansoprazole
,7587960,plasma unbound fractions,"The volumes of distribution at steady-state were 0.66 liter/kg for OPZ and 1.04 liter/kg for LPZ, and the plasma unbound fractions were 0.105 and 0.069.","Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587960/),,0.105,5166,DB00448,Lansoprazole
,7587960,plasma unbound fractions,"The volumes of distribution at steady-state were 0.66 liter/kg for OPZ and 1.04 liter/kg for LPZ, and the plasma unbound fractions were 0.105 and 0.069.","Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587960/),,0.069,5167,DB00448,Lansoprazole
,7587960,Second-order rate constants,"Second-order rate constants for association of OPZ or LPZ and H+,K+-ATPase based on a PK/PD model were 72.5 +/- 30.0 (estimated value +/- SD) and 124 +/- 58 ml/micrograms/hr respectively.","Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587960/),[ml] / [h·μg],72.5,5168,DB00448,Lansoprazole
,7587960,Second-order rate constants,"Second-order rate constants for association of OPZ or LPZ and H+,K+-ATPase based on a PK/PD model were 72.5 +/- 30.0 (estimated value +/- SD) and 124 +/- 58 ml/micrograms/hr respectively.","Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587960/),[ml] / [h·μg],124,5169,DB00448,Lansoprazole
,7587960,Apparent turnover rate,"Apparent turnover rate of H+,K+-ATPase was 8.8 hr as half-life, assuming the same value for both drugs.","Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587960/),h,8.8,5170,DB00448,Lansoprazole
,16503713,AUC(0-24),The mean +/- SD AUC(0-24) for phase A was 16.3 +/- 9.0 microM x hour versus 0.95 +/- 1.8 microM x hour for phase B (p<0.01).,Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16503713/),h·μM,16.3,5810,DB00448,Lansoprazole
,16503713,AUC(0-24),The mean +/- SD AUC(0-24) for phase A was 16.3 +/- 9.0 microM x hour versus 0.95 +/- 1.8 microM x hour for phase B (p<0.01).,Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16503713/),h·μM,0.95,5811,DB00448,Lansoprazole
,16503713,maximum concentration,The mean +/- SD maximum concentration of atazanavir was 3.2 +/- 1.7 microM for phase A and 0.13 +/- 0.19 microM for phase B (p<0.01).,Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16503713/),μM,3.2,5812,DB00448,Lansoprazole
,16503713,maximum concentration,The mean +/- SD maximum concentration of atazanavir was 3.2 +/- 1.7 microM for phase A and 0.13 +/- 0.19 microM for phase B (p<0.01).,Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16503713/),μM,0.13,5813,DB00448,Lansoprazole
,18223462,Cmax,"The mean dose-unadjusted and -adjusted Cmax of MPA with 30 mg lansoprazole were significantly lower than those without PPI (11.8 vs. 17.8 microg/mL, P = 0.0197, and 22.6 vs. 33.1 ng/mL/mg MMF, P = 0.0222, respectively).",Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223462/),[μg] / [ml],11.8,9335,DB00448,Lansoprazole
,18223462,Cmax,"The mean dose-unadjusted and -adjusted Cmax of MPA with 30 mg lansoprazole were significantly lower than those without PPI (11.8 vs. 17.8 microg/mL, P = 0.0197, and 22.6 vs. 33.1 ng/mL/mg MMF, P = 0.0222, respectively).",Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223462/),[μg] / [ml],17.8,9336,DB00448,Lansoprazole
,18223462,Cmax,"The mean dose-unadjusted and -adjusted Cmax of MPA with 30 mg lansoprazole were significantly lower than those without PPI (11.8 vs. 17.8 microg/mL, P = 0.0197, and 22.6 vs. 33.1 ng/mL/mg MMF, P = 0.0222, respectively).",Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223462/),[ng] / [mg·ml],22.6,9337,DB00448,Lansoprazole
,18223462,Cmax,"The mean dose-unadjusted and -adjusted Cmax of MPA with 30 mg lansoprazole were significantly lower than those without PPI (11.8 vs. 17.8 microg/mL, P = 0.0197, and 22.6 vs. 33.1 ng/mL/mg MMF, P = 0.0222, respectively).",Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223462/),[ng] / [mg·ml],33.1,9338,DB00448,Lansoprazole
>,10071967,Recoveries,Recoveries of the analytes and internal standard were >75.48%.,Advanced method for determination of omeprazole in plasma by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071967/),%,75.48,9803,DB00448,Lansoprazole
,10071967,detection limit,The detection limit in plasma was 2 ng/ml.,Advanced method for determination of omeprazole in plasma by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071967/),[ng] / [ml],2,9804,DB00448,Lansoprazole
,22147077,dose,"The only variable factor, the dasatinib dose-adjusted AUC(0-4) for patients administered an H2RA or PPI, was significantly lower than for patients not administered an acid suppressant (median (quartile 1-quartile 3) values: 1.47 (0.79-2.29) versus 3.51 (2.50-5.45) ng h/mL/mg, respectively, P = 0.0008).",Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22147077/),[h·ng] / [mg·ml],1.47,11921,DB00448,Lansoprazole
,22147077,AUC(0-4),"The only variable factor, the dasatinib dose-adjusted AUC(0-4) for patients administered an H2RA or PPI, was significantly lower than for patients not administered an acid suppressant (median (quartile 1-quartile 3) values: 1.47 (0.79-2.29) versus 3.51 (2.50-5.45) ng h/mL/mg, respectively, P = 0.0008).",Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22147077/),[h·ng] / [mg·ml],1.47,11922,DB00448,Lansoprazole
,22147077,AUC(0-4),"The only variable factor, the dasatinib dose-adjusted AUC(0-4) for patients administered an H2RA or PPI, was significantly lower than for patients not administered an acid suppressant (median (quartile 1-quartile 3) values: 1.47 (0.79-2.29) versus 3.51 (2.50-5.45) ng h/mL/mg, respectively, P = 0.0008).",Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22147077/),[h·ng] / [mg·ml],3.51,11923,DB00448,Lansoprazole
,21730117,MIC(90),"Among these agents, sitafloxacin (a fluoroquinolone) showed the greatest activity (MIC(90), 0.06 μg/ml), with high bactericidal activity and synergy in sitafloxacin-lansoprazole (a proton pump inhibitor) combination.",Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21730117/),[μg] / [ml],0.06,18754,DB00448,Lansoprazole
,21730117,MIC,"In a Mongolian gerbil model with a H. pylori ATCC 43504 challenge, marked eradication effects were observed at ≥1 mg/kg for sitafloxacin, ≥10 mg/kg for levofloxacin, and ≥10 mg/kg for lansoprazole, reflecting MIC levels for each agent (0.008, 0.25, and 2 μg/ml, respectively).",Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21730117/),[μg] / [ml],0.008,18755,DB00448,Lansoprazole
,21730117,MIC,"In a Mongolian gerbil model with a H. pylori ATCC 43504 challenge, marked eradication effects were observed at ≥1 mg/kg for sitafloxacin, ≥10 mg/kg for levofloxacin, and ≥10 mg/kg for lansoprazole, reflecting MIC levels for each agent (0.008, 0.25, and 2 μg/ml, respectively).",Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21730117/),[μg] / [ml],0.25,18756,DB00448,Lansoprazole
,21730117,MIC,"In a Mongolian gerbil model with a H. pylori ATCC 43504 challenge, marked eradication effects were observed at ≥1 mg/kg for sitafloxacin, ≥10 mg/kg for levofloxacin, and ≥10 mg/kg for lansoprazole, reflecting MIC levels for each agent (0.008, 0.25, and 2 μg/ml, respectively).",Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21730117/),[μg] / [ml],2,18757,DB00448,Lansoprazole
,21730117,therapeutic rates,The therapeutic rates were 83.3% for the sitafloxacin (0.3 mg/kg)-lansoprazole (2.5 mg/kg) combination and 0% for either sitafloxacin or lansoprazole alone.,Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21730117/),%,83,18758,DB00448,Lansoprazole
,21730117,therapeutic rates,The therapeutic rates were 83.3% for the sitafloxacin (0.3 mg/kg)-lansoprazole (2.5 mg/kg) combination and 0% for either sitafloxacin or lansoprazole alone.,Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21730117/),%,0,18759,DB00448,Lansoprazole
,21730117,maximum serum concentration (C(max)),"The maximum serum concentration (C(max)) of sitafloxacin was 0.080 ± 0.054 μg/ml at 30 min, when orally administered at 1 mg/kg.",Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21730117/),[μg] / [ml],0.080,18760,DB00448,Lansoprazole
,23229306,C max,"After single and multiple i.v. doses of 30 mg LPZ, the C max values of LPZ, HLPZ and LPZS were 1490 ± 290 and 1450 ± 280, 175 ± 71 and 154 ± 56, and 51.3 ± 82.9 and 74.1 ± 158.7 ng/mL, with the AUC0-t values 3280 ± 2550 and 4260 ± 3880, 381 ± 128 and 389 ± 111, and 389 ± 1204 and 700 ± 2255 ng h/mL, respectively.",Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229306/),[ng] / [ml],1490,22364,DB00448,Lansoprazole
,23229306,C max,"After single and multiple i.v. doses of 30 mg LPZ, the C max values of LPZ, HLPZ and LPZS were 1490 ± 290 and 1450 ± 280, 175 ± 71 and 154 ± 56, and 51.3 ± 82.9 and 74.1 ± 158.7 ng/mL, with the AUC0-t values 3280 ± 2550 and 4260 ± 3880, 381 ± 128 and 389 ± 111, and 389 ± 1204 and 700 ± 2255 ng h/mL, respectively.",Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229306/),[ng] / [ml],1450,22365,DB00448,Lansoprazole
,23229306,C max,"After single and multiple i.v. doses of 30 mg LPZ, the C max values of LPZ, HLPZ and LPZS were 1490 ± 290 and 1450 ± 280, 175 ± 71 and 154 ± 56, and 51.3 ± 82.9 and 74.1 ± 158.7 ng/mL, with the AUC0-t values 3280 ± 2550 and 4260 ± 3880, 381 ± 128 and 389 ± 111, and 389 ± 1204 and 700 ± 2255 ng h/mL, respectively.",Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229306/),[ng] / [ml],175,22366,DB00448,Lansoprazole
,23229306,C max,"After single and multiple i.v. doses of 30 mg LPZ, the C max values of LPZ, HLPZ and LPZS were 1490 ± 290 and 1450 ± 280, 175 ± 71 and 154 ± 56, and 51.3 ± 82.9 and 74.1 ± 158.7 ng/mL, with the AUC0-t values 3280 ± 2550 and 4260 ± 3880, 381 ± 128 and 389 ± 111, and 389 ± 1204 and 700 ± 2255 ng h/mL, respectively.",Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229306/),[ng] / [ml],154,22367,DB00448,Lansoprazole
,23229306,C max,"After single and multiple i.v. doses of 30 mg LPZ, the C max values of LPZ, HLPZ and LPZS were 1490 ± 290 and 1450 ± 280, 175 ± 71 and 154 ± 56, and 51.3 ± 82.9 and 74.1 ± 158.7 ng/mL, with the AUC0-t values 3280 ± 2550 and 4260 ± 3880, 381 ± 128 and 389 ± 111, and 389 ± 1204 and 700 ± 2255 ng h/mL, respectively.",Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229306/),[ng] / [ml],51.3,22368,DB00448,Lansoprazole
,23229306,C max,"After single and multiple i.v. doses of 30 mg LPZ, the C max values of LPZ, HLPZ and LPZS were 1490 ± 290 and 1450 ± 280, 175 ± 71 and 154 ± 56, and 51.3 ± 82.9 and 74.1 ± 158.7 ng/mL, with the AUC0-t values 3280 ± 2550 and 4260 ± 3880, 381 ± 128 and 389 ± 111, and 389 ± 1204 and 700 ± 2255 ng h/mL, respectively.",Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229306/),[ng] / [ml],74.1,22369,DB00448,Lansoprazole
,23229306,AUC0-t,"After single and multiple i.v. doses of 30 mg LPZ, the C max values of LPZ, HLPZ and LPZS were 1490 ± 290 and 1450 ± 280, 175 ± 71 and 154 ± 56, and 51.3 ± 82.9 and 74.1 ± 158.7 ng/mL, with the AUC0-t values 3280 ± 2550 and 4260 ± 3880, 381 ± 128 and 389 ± 111, and 389 ± 1204 and 700 ± 2255 ng h/mL, respectively.",Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229306/),[h·ng] / [ml],3280,22370,DB00448,Lansoprazole
,23229306,AUC0-t,"After single and multiple i.v. doses of 30 mg LPZ, the C max values of LPZ, HLPZ and LPZS were 1490 ± 290 and 1450 ± 280, 175 ± 71 and 154 ± 56, and 51.3 ± 82.9 and 74.1 ± 158.7 ng/mL, with the AUC0-t values 3280 ± 2550 and 4260 ± 3880, 381 ± 128 and 389 ± 111, and 389 ± 1204 and 700 ± 2255 ng h/mL, respectively.",Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229306/),[h·ng] / [ml],4260,22371,DB00448,Lansoprazole
,23229306,AUC0-t,"After single and multiple i.v. doses of 30 mg LPZ, the C max values of LPZ, HLPZ and LPZS were 1490 ± 290 and 1450 ± 280, 175 ± 71 and 154 ± 56, and 51.3 ± 82.9 and 74.1 ± 158.7 ng/mL, with the AUC0-t values 3280 ± 2550 and 4260 ± 3880, 381 ± 128 and 389 ± 111, and 389 ± 1204 and 700 ± 2255 ng h/mL, respectively.",Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229306/),[h·ng] / [ml],381,22372,DB00448,Lansoprazole
,23229306,AUC0-t,"After single and multiple i.v. doses of 30 mg LPZ, the C max values of LPZ, HLPZ and LPZS were 1490 ± 290 and 1450 ± 280, 175 ± 71 and 154 ± 56, and 51.3 ± 82.9 and 74.1 ± 158.7 ng/mL, with the AUC0-t values 3280 ± 2550 and 4260 ± 3880, 381 ± 128 and 389 ± 111, and 389 ± 1204 and 700 ± 2255 ng h/mL, respectively.",Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229306/),[h·ng] / [ml],389,22373,DB00448,Lansoprazole
,23229306,AUC0-t,"After single and multiple i.v. doses of 30 mg LPZ, the C max values of LPZ, HLPZ and LPZS were 1490 ± 290 and 1450 ± 280, 175 ± 71 and 154 ± 56, and 51.3 ± 82.9 and 74.1 ± 158.7 ng/mL, with the AUC0-t values 3280 ± 2550 and 4260 ± 3880, 381 ± 128 and 389 ± 111, and 389 ± 1204 and 700 ± 2255 ng h/mL, respectively.",Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229306/),[h·ng] / [ml],389,22374,DB00448,Lansoprazole
,23229306,AUC0-t,"After single and multiple i.v. doses of 30 mg LPZ, the C max values of LPZ, HLPZ and LPZS were 1490 ± 290 and 1450 ± 280, 175 ± 71 and 154 ± 56, and 51.3 ± 82.9 and 74.1 ± 158.7 ng/mL, with the AUC0-t values 3280 ± 2550 and 4260 ± 3880, 381 ± 128 and 389 ± 111, and 389 ± 1204 and 700 ± 2255 ng h/mL, respectively.",Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229306/),[h·ng] / [ml],700,22375,DB00448,Lansoprazole
,23229306,t 1/2,"The t 1/2 and CL values of LPZ after single and multiple i.v. doses were 1.48 ± 1.03 and 2.19 ± 1.03 h, and 11.67 ± 4.49 and 9.56 ± 4.08 L/h, respectively.",Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229306/),h,1.48,22376,DB00448,Lansoprazole
,23229306,t 1/2,"The t 1/2 and CL values of LPZ after single and multiple i.v. doses were 1.48 ± 1.03 and 2.19 ± 1.03 h, and 11.67 ± 4.49 and 9.56 ± 4.08 L/h, respectively.",Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229306/),[l] / [h],11.67,22377,DB00448,Lansoprazole
,23229306,CL,"The t 1/2 and CL values of LPZ after single and multiple i.v. doses were 1.48 ± 1.03 and 2.19 ± 1.03 h, and 11.67 ± 4.49 and 9.56 ± 4.08 L/h, respectively.",Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229306/),h,2.19,22378,DB00448,Lansoprazole
,23229306,CL,"The t 1/2 and CL values of LPZ after single and multiple i.v. doses were 1.48 ± 1.03 and 2.19 ± 1.03 h, and 11.67 ± 4.49 and 9.56 ± 4.08 L/h, respectively.",Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229306/),[l] / [h],9.56,22379,DB00448,Lansoprazole
,27628584,Cmax,Neratinib geometric least-squares mean (LSM) Cmax was reduced from 84.5 ng ml-1 with neratinib alone to 24.5 ng ml-1 with neratinib plus lansoprazole.,Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27628584/),[ng] / [ml],84.5,26226,DB00448,Lansoprazole
,27628584,Cmax,Neratinib geometric least-squares mean (LSM) Cmax was reduced from 84.5 ng ml-1 with neratinib alone to 24.5 ng ml-1 with neratinib plus lansoprazole.,Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27628584/),[ng] / [ml],24.5,26227,DB00448,Lansoprazole
,27628584,AUC0-t,The extent of exposure to neratinib was also decreased: geometric LSM AUC0-t was 1478 ng ml-1 h with neratinib vs.,Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27628584/),[h·ng] / [ml],1478,26228,DB00448,Lansoprazole
,27628584,AUC0-inf,"426 ng ml-1 h with neratinib plus lansoprazole, and geometric LSM AUC0-inf was 1557 ng ml-1 h vs. 542 ng ml-1 h, respectively.",Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27628584/),[h·ng] / [ml],1557,26229,DB00448,Lansoprazole
,27628584,AUC0-inf,"426 ng ml-1 h with neratinib plus lansoprazole, and geometric LSM AUC0-inf was 1557 ng ml-1 h vs. 542 ng ml-1 h, respectively.",Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27628584/),[h·ng] / [ml],542,26230,DB00448,Lansoprazole
,27628584,t½,Mean t½ was similar with both treatments (approximately 14 h).,Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27628584/),h,14,26231,DB00448,Lansoprazole
,30030850,Rs,"Satisfactory resolution (Rs = 2.0) was achieved within 7.3 min on a Chiralpak ID column (250 × 4.6 mm, 5 μm) employing acetonitrile-water (60:40, v/v) as the mobile phase at a flow rate of 0.6 mL/min.",Enantioselective analysis of lansoprazole in rat plasma by LC-MS/MS: Application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30030850/),,2.0,27316,DB00448,Lansoprazole
,30030850,flow rate,"Satisfactory resolution (Rs = 2.0) was achieved within 7.3 min on a Chiralpak ID column (250 × 4.6 mm, 5 μm) employing acetonitrile-water (60:40, v/v) as the mobile phase at a flow rate of 0.6 mL/min.",Enantioselective analysis of lansoprazole in rat plasma by LC-MS/MS: Application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30030850/),[ml] / [min],0.6,27317,DB00448,Lansoprazole
,16487225,relative AUC ratios,"The area under the plasma concentration-time curves (AUC) of (R)-rabeprazole in homEMs, hetEMs and PMs were 1.8-, 2.2- and 2.4-fold, respectively, greater than those of (S)-rabeprazole; the relative AUC ratios of (R)- and (S)-rabeprazole in homEMs, hetEMs and PMs were 1:1.1:2.1 and 1:0.9:1.5, respectively.",Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487225/),,1,30554,DB00448,Lansoprazole
,16487225,elimination half-life,"There was no difference between homEMs and PMs in the elimination half-life of (S)-rabeprazole, whereas the elimination half-life of (R)-rabeprazole was significantly longer in PMs than in homEMs [1.7 h (1.4, 2.0) (mean (95% confidence interval)]vs. 0.8 h (0.6, 1.0), respectively, P<0.0001).",Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487225/),h,1.7,30555,DB00448,Lansoprazole
,16487225,elimination half-life,"There was no difference between homEMs and PMs in the elimination half-life of (S)-rabeprazole, whereas the elimination half-life of (R)-rabeprazole was significantly longer in PMs than in homEMs [1.7 h (1.4, 2.0) (mean (95% confidence interval)]vs. 0.8 h (0.6, 1.0), respectively, P<0.0001).",Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487225/),h,0.8,30556,DB00448,Lansoprazole
,12607792,C(max),"Mean lansoprazole C(max) values of 790.9 ng/mL and 898.5 ng/mL and T(max) values of 1.5 hours and 1.7 hours were observed in the < or = 30 kg and the > 30 kg body weight treatment groups, respectively.",Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607792/),[ng] / [ml],790.9,34854,DB00448,Lansoprazole
,12607792,C(max),"Mean lansoprazole C(max) values of 790.9 ng/mL and 898.5 ng/mL and T(max) values of 1.5 hours and 1.7 hours were observed in the < or = 30 kg and the > 30 kg body weight treatment groups, respectively.",Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607792/),[ng] / [ml],898.5,34855,DB00448,Lansoprazole
,12607792,T(max),"Mean lansoprazole C(max) values of 790.9 ng/mL and 898.5 ng/mL and T(max) values of 1.5 hours and 1.7 hours were observed in the < or = 30 kg and the > 30 kg body weight treatment groups, respectively.",Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607792/),h,1.5,34856,DB00448,Lansoprazole
,12607792,T(max),"Mean lansoprazole C(max) values of 790.9 ng/mL and 898.5 ng/mL and T(max) values of 1.5 hours and 1.7 hours were observed in the < or = 30 kg and the > 30 kg body weight treatment groups, respectively.",Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607792/),h,1.7,34857,DB00448,Lansoprazole
,12607792,AUC0-24,"AUC0-24 values of 1707 ng x h/mL and 1883 ng x h/mL and T1/2 values of 0.68 hours and 0.71 hours were observed in the < or = 30 kg and > 30 kg lansoprazole body weight treatment groups, respectively.",Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607792/),[h·ng] / [ml],1707,34858,DB00448,Lansoprazole
,12607792,AUC0-24,"AUC0-24 values of 1707 ng x h/mL and 1883 ng x h/mL and T1/2 values of 0.68 hours and 0.71 hours were observed in the < or = 30 kg and > 30 kg lansoprazole body weight treatment groups, respectively.",Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607792/),[h·ng] / [ml],1883,34859,DB00448,Lansoprazole
,12607792,T1/2,"AUC0-24 values of 1707 ng x h/mL and 1883 ng x h/mL and T1/2 values of 0.68 hours and 0.71 hours were observed in the < or = 30 kg and > 30 kg lansoprazole body weight treatment groups, respectively.",Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607792/),h,0.68,34860,DB00448,Lansoprazole
,12607792,T1/2,"AUC0-24 values of 1707 ng x h/mL and 1883 ng x h/mL and T1/2 values of 0.68 hours and 0.71 hours were observed in the < or = 30 kg and > 30 kg lansoprazole body weight treatment groups, respectively.",Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607792/),h,0.71,34861,DB00448,Lansoprazole
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.38,37476,DB00448,Lansoprazole
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.15,37477,DB00448,Lansoprazole
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.13,37478,DB00448,Lansoprazole
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.05,37479,DB00448,Lansoprazole
,28801980,IC50,"Moreover, in vitro experiments demonstrated that PPIs (esomeprazole, lansoprazole, omeprazole and rabeprazole) inhibited hOAT3-mediated uptake of MTX in a concentration-dependent manner (IC50 values of 0.40-5.5 μ m), with a rank order of lansoprazole > esomeprazole > rabeprazole > omeprazole.",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),m·μ,0.40-5.5,37480,DB00448,Lansoprazole
,28138748,Total clearance,"Total clearance and half-life (t1/2) was independent of dose, and ranged from 4.69 L/h to 5.85 L/h and from 1.24 h to 2.17 h, respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy Chinese subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28138748/),[l] / [h],4.69,39514,DB00448,Lansoprazole
,28138748,half-life (t1/2),"Total clearance and half-life (t1/2) was independent of dose, and ranged from 4.69 L/h to 5.85 L/h and from 1.24 h to 2.17 h, respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy Chinese subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28138748/),[l] / [h],5.85,39515,DB00448,Lansoprazole
,28138748,half-life (t1/2),"Total clearance and half-life (t1/2) was independent of dose, and ranged from 4.69 L/h to 5.85 L/h and from 1.24 h to 2.17 h, respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy Chinese subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28138748/),h,1.24,39516,DB00448,Lansoprazole
,28138748,half-life (t1/2),"Total clearance and half-life (t1/2) was independent of dose, and ranged from 4.69 L/h to 5.85 L/h and from 1.24 h to 2.17 h, respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy Chinese subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28138748/),h,2.17,39517,DB00448,Lansoprazole
,12011821,maximal concentration (C(max)),"In group A, maximal concentration (C(max)) was 1023 +/- 775 (mg. L(-1))/(17 mg.",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),[-1·mg] / [l],1023,40444,DB00448,Lansoprazole
,12011821,time to reach C(max),"m(-2)), time to reach C(max) was 1.8 +/- 0.8 hours, elimination half-life was 1.5 +/- 2.0 hours, area under the concentration-time curve from time zero to infinity [AUC(0-infinity)] was 3503 +/- 6025 (mg. L(-1).",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),h,1.8,40445,DB00448,Lansoprazole
,12011821,elimination half-life,"m(-2)), time to reach C(max) was 1.8 +/- 0.8 hours, elimination half-life was 1.5 +/- 2.0 hours, area under the concentration-time curve from time zero to infinity [AUC(0-infinity)] was 3503 +/- 6025 (mg. L(-1).",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),h,1.5,40446,DB00448,Lansoprazole
,12011821,area under the concentration-time curve from time zero to infinity [AUC(0-infinity)],"m(-2)), time to reach C(max) was 1.8 +/- 0.8 hours, elimination half-life was 1.5 +/- 2.0 hours, area under the concentration-time curve from time zero to infinity [AUC(0-infinity)] was 3503 +/- 6025 (mg. L(-1).",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),[mg] / [l],3503,40447,DB00448,Lansoprazole
,12011821,apparent plasma clearance,"m(-2)), apparent plasma clearance was 0.57 +/- 0.47 L. h(-1).",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),[l] / [h],0.57,40448,DB00448,Lansoprazole
,12011821,apparent volume of distribution,"kg(-1), and apparent volume of distribution was 0.61 +/- 0.36 L. kg(-1).",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),[l] / [kg],0.61,40449,DB00448,Lansoprazole
,12011821,C(max),"In group B, C(max) was 750 +/- 511 (mg. L(-1))/(17 mg.",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),[-1·mg] / [l],750,40450,DB00448,Lansoprazole
,12011821,time to reach C(max),"m(-2)), time to reach C(max) was 1.8 +/- 1.1 hours, elimination half-life was 1.2 +/- 1.1 hours, AUC(0-infinity) was 2351 +/- 3691 (mg. L(-1).",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),h,1.8,40451,DB00448,Lansoprazole
,12011821,elimination half-life,"m(-2)), time to reach C(max) was 1.8 +/- 1.1 hours, elimination half-life was 1.2 +/- 1.1 hours, AUC(0-infinity) was 2351 +/- 3691 (mg. L(-1).",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),h,1.2,40452,DB00448,Lansoprazole
,12011821,AUC(0-infinity),"m(-2)), time to reach C(max) was 1.8 +/- 1.1 hours, elimination half-life was 1.2 +/- 1.1 hours, AUC(0-infinity) was 2351 +/- 3691 (mg. L(-1).",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),[mg] / [l],2351,40453,DB00448,Lansoprazole
,12011821,apparent plasma clearance,"m(-2)), apparent plasma clearance was 0.71 +/- 0.50 L. h(-1).",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),[l] / [h],0.71,40454,DB00448,Lansoprazole
,12011821,apparent volume of distribution,"kg(-1), and apparent volume of distribution was 0.9 +/- 0.7 L. kg(-1).",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),[l] / [kg],0.9,40455,DB00448,Lansoprazole
,12011821,percentage of time,"The values for 24-hour percentage of time at gastric pH <4 and pH <3 were 61% +/- 21% and 51% +/- 21% (group A) and 47% +/- 24% and 37% +/- 21% (group B), respectively.",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),%,61,40456,DB00448,Lansoprazole
,12011821,percentage of time,"The values for 24-hour percentage of time at gastric pH <4 and pH <3 were 61% +/- 21% and 51% +/- 21% (group A) and 47% +/- 24% and 37% +/- 21% (group B), respectively.",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),%,51,40457,DB00448,Lansoprazole
,12011821,percentage of time,"The values for 24-hour percentage of time at gastric pH <4 and pH <3 were 61% +/- 21% and 51% +/- 21% (group A) and 47% +/- 24% and 37% +/- 21% (group B), respectively.",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),%,47,40458,DB00448,Lansoprazole
,12011821,percentage of time,"The values for 24-hour percentage of time at gastric pH <4 and pH <3 were 61% +/- 21% and 51% +/- 21% (group A) and 47% +/- 24% and 37% +/- 21% (group B), respectively.",Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12011821/),%,37,40459,DB00448,Lansoprazole
,18076214,elimination half-lives,The currently available PPIs have short elimination half-lives ranging from 1 to 1.5 hours.,Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18076214/),h,1 to 1.5,42062,DB00448,Lansoprazole
,19238367,C(max),"On day 1, the mean C(max) of lansoprazole in the T/T group was significantly higher than that in the C/C or C/T groups (T/T 1,248, C/C 618, C/T 607 ng/ml; P = 0.038).",Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238367/),[ng] / [ml],"1,248",47627,DB00448,Lansoprazole
,19238367,C(max),"On day 1, the mean C(max) of lansoprazole in the T/T group was significantly higher than that in the C/C or C/T groups (T/T 1,248, C/C 618, C/T 607 ng/ml; P = 0.038).",Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238367/),[ng] / [ml],618,47628,DB00448,Lansoprazole
,19238367,C/C,"On day 1, the mean C(max) of lansoprazole in the T/T group was significantly higher than that in the C/C or C/T groups (T/T 1,248, C/C 618, C/T 607 ng/ml; P = 0.038).",Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238367/),[ng] / [ml],618,47629,DB00448,Lansoprazole
,19238367,C/T,"On day 1, the mean C(max) of lansoprazole in the T/T group was significantly higher than that in the C/C or C/T groups (T/T 1,248, C/C 618, C/T 607 ng/ml; P = 0.038).",Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238367/),[ng] / [ml],607,47630,DB00448,Lansoprazole
,7656504,plasma elimination half-life (t1/2),Mean plasma elimination half-life (t1/2) is between 1.3 and 2.1 hours in healthy volunteers.,Clinical pharmacokinetics of lansoprazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7656504/),h,1.3 and 2.1,47682,DB00448,Lansoprazole
,30216801,VRC,"Interestingly, patients in the PPIs groups were more likely to reach the therapeutic VRC range of 1-5.5 μg/mL in steady state when compared with control patients (75-81% VS 69%).",The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30216801/),[μg] / [ml],1-5.5,56720,DB00448,Lansoprazole
,18057705,volume of the central,"The mean volume of the central and peripheral compartments was 0.110 and 0.201 l/kg, respectively.",Population pharmacokinetics and proton pump inhibitory effects of intravenous lansoprazole in healthy Japanese males. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18057705/),[l] / [kg],0.110,60506,DB00448,Lansoprazole
,18057705,volume of the central,"The mean volume of the central and peripheral compartments was 0.110 and 0.201 l/kg, respectively.",Population pharmacokinetics and proton pump inhibitory effects of intravenous lansoprazole in healthy Japanese males. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18057705/),[l] / [kg],0.201,60507,DB00448,Lansoprazole
,18057705,inter-compartment clearance,The mean inter-compartment clearance was estimated to be 0.0882 l/h/kg.,Population pharmacokinetics and proton pump inhibitory effects of intravenous lansoprazole in healthy Japanese males. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18057705/),[l] / [h·kg],0.0882,60508,DB00448,Lansoprazole
,18057705,systemic clearance,"The population mean value of systemic clearance in the homoEM (CYP2C19 1/ 1), heteroEM (CYP2C19 1/2 and 1/3), and PM (CYP2C19 2/2, 2/3, and 3/3) groups was 0.179, 0.109, and 0.038 l/h/kg, respectively.",Population pharmacokinetics and proton pump inhibitory effects of intravenous lansoprazole in healthy Japanese males. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18057705/),[l] / [h·kg],0.179,60509,DB00448,Lansoprazole
,18057705,systemic clearance,"The population mean value of systemic clearance in the homoEM (CYP2C19 1/ 1), heteroEM (CYP2C19 1/2 and 1/3), and PM (CYP2C19 2/2, 2/3, and 3/3) groups was 0.179, 0.109, and 0.038 l/h/kg, respectively.",Population pharmacokinetics and proton pump inhibitory effects of intravenous lansoprazole in healthy Japanese males. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18057705/),[l] / [h·kg],0.109,60510,DB00448,Lansoprazole
,18057705,systemic clearance,"The population mean value of systemic clearance in the homoEM (CYP2C19 1/ 1), heteroEM (CYP2C19 1/2 and 1/3), and PM (CYP2C19 2/2, 2/3, and 3/3) groups was 0.179, 0.109, and 0.038 l/h/kg, respectively.",Population pharmacokinetics and proton pump inhibitory effects of intravenous lansoprazole in healthy Japanese males. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18057705/),[l] / [h·kg],0.038,60511,DB00448,Lansoprazole
,15448955,R/S ratios,"The R/S ratios for the AUC of lansoprazole for the homEMs, hetEMs and PMs were 12.7, 8.5 and 5.8, respectively, suggesting a significant effect of CYP2C19 polymorphisms on the stereoselective disposition of lansoprazole.","Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15448955/),,12.7,62545,DB00448,Lansoprazole
,15448955,R/S ratios,"The R/S ratios for the AUC of lansoprazole for the homEMs, hetEMs and PMs were 12.7, 8.5 and 5.8, respectively, suggesting a significant effect of CYP2C19 polymorphisms on the stereoselective disposition of lansoprazole.","Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15448955/),,8.5,62546,DB00448,Lansoprazole
,15448955,R/S ratios,"The R/S ratios for the AUC of lansoprazole for the homEMs, hetEMs and PMs were 12.7, 8.5 and 5.8, respectively, suggesting a significant effect of CYP2C19 polymorphisms on the stereoselective disposition of lansoprazole.","Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15448955/),,5.8,62547,DB00448,Lansoprazole
,16012079,Cmax,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],954,66805,DB00448,Lansoprazole
,16012079,Cmax,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],167,66806,DB00448,Lansoprazole
,16012079,AUC0-24,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],167,66807,DB00448,Lansoprazole
,16012079,AUC0-24,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[nghml],4787,66808,DB00448,Lansoprazole
,16012079,AUC0-24,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[nghml],451,66809,DB00448,Lansoprazole
,16012079,elimination half-life,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,2.3,66810,DB00448,Lansoprazole
,16012079,elimination half-life,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,1.2,66811,DB00448,Lansoprazole
,16012079,elimination half-life,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,2.1,66812,DB00448,Lansoprazole
,16012079,elimination half-life,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,1.3,66813,DB00448,Lansoprazole
,16012079,Cmax,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],186,66814,DB00448,Lansoprazole
,16012079,Cmax,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],200,66815,DB00448,Lansoprazole
,16573800,pH,"Mean intragastric pH values for lansoprazole regimens ranged from 4.8 to 5.2 (0-24 h), 5.5 to 6.0 (>24 to 48 h) and 5.2 to 5.6 (0-48 h).",Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16573800/),,4.8 to 5.2,67393,DB00448,Lansoprazole
,16573800,pH,"Mean intragastric pH values for lansoprazole regimens ranged from 4.8 to 5.2 (0-24 h), 5.5 to 6.0 (>24 to 48 h) and 5.2 to 5.6 (0-48 h).",Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16573800/),,5.5 to 6.0,67394,DB00448,Lansoprazole
,16573800,pH,"Mean intragastric pH values for lansoprazole regimens ranged from 4.8 to 5.2 (0-24 h), 5.5 to 6.0 (>24 to 48 h) and 5.2 to 5.6 (0-48 h).",Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16573800/),,5.2 to 5.6,67395,DB00448,Lansoprazole
,16573800,systemic clearance,"The mean systemic clearance of lansoprazole was lower in CYP2C19 heterozygous metabolizers than in homozygous extensive metabolizers (9.2 vs. 16.5 L/h), with substantial variability resulting in overlapping ranges of clearance values for both subpopulations.",Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16573800/),[l] / [h],9.2,67396,DB00448,Lansoprazole
,16573800,systemic clearance,"The mean systemic clearance of lansoprazole was lower in CYP2C19 heterozygous metabolizers than in homozygous extensive metabolizers (9.2 vs. 16.5 L/h), with substantial variability resulting in overlapping ranges of clearance values for both subpopulations.",Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16573800/),[l] / [h],16.5,67397,DB00448,Lansoprazole
,15652200,C(max),"After small intestinal administration of LPZ, 5.0 mg/kg, solution with HCO-60 showed the highest plasma LPZ concentration versus time curve of which C(max) and AUC was 0.46+/-0.01 microg/mL and 0.73+/-0.03 microgh/mL.",Effect of adsorbents on the absorption of lansoprazole with surfactant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652200/),[μg] / [ml],0.46,72253,DB00448,Lansoprazole
,15652200,AUC,"After small intestinal administration of LPZ, 5.0 mg/kg, solution with HCO-60 showed the highest plasma LPZ concentration versus time curve of which C(max) and AUC was 0.46+/-0.01 microg/mL and 0.73+/-0.03 microgh/mL.",Effect of adsorbents on the absorption of lansoprazole with surfactant. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652200/),[μgh] / [ml],0.73,72254,DB00448,Lansoprazole
,15652200,BA,"By comparing to that after i.v. injection of LPZ solution, 2.0 mg/kg, the BA of LPZ from HCO-60 solution was 39.0%, which was about seven times higher than that of LPZ powder.",Effect of adsorbents on the absorption of lansoprazole with surfactant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652200/),%,39.0,72255,DB00448,Lansoprazole
,15652200,T50%,"Sylysia 320, Neusilin S2 and Neusilin NS2 showed the T50% of about 1h.",Effect of adsorbents on the absorption of lansoprazole with surfactant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652200/),h,1,72256,DB00448,Lansoprazole
,15652200,AUC,The AUC of Sylysia 550 system was 2.16+/-0.26 microgh/mL and was greater than enteric tablet and the BA of 71.7% was obtained.,Effect of adsorbents on the absorption of lansoprazole with surfactant. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652200/),[μgh] / [ml],2.16,72257,DB00448,Lansoprazole
,17204950,time to reach maximum concentration,"Pharmacokinetic analysis of 5 children found a mean time to reach maximum concentration of 1.4 h, maximal plasma concentrations of 894 ng/mL, area under the concentration time curve of 1906 ng * h/mL and a half-life of 0.66 h.",Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17204950/),h,1.4,72458,DB00448,Lansoprazole
,17204950,maximal plasma concentrations,"Pharmacokinetic analysis of 5 children found a mean time to reach maximum concentration of 1.4 h, maximal plasma concentrations of 894 ng/mL, area under the concentration time curve of 1906 ng * h/mL and a half-life of 0.66 h.",Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17204950/),[ng] / [ml],894,72459,DB00448,Lansoprazole
,17204950,area under the concentration time curve,"Pharmacokinetic analysis of 5 children found a mean time to reach maximum concentration of 1.4 h, maximal plasma concentrations of 894 ng/mL, area under the concentration time curve of 1906 ng * h/mL and a half-life of 0.66 h.",Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17204950/),[h·ng] / [ml],1906,72460,DB00448,Lansoprazole
,17204950,half-life,"Pharmacokinetic analysis of 5 children found a mean time to reach maximum concentration of 1.4 h, maximal plasma concentrations of 894 ng/mL, area under the concentration time curve of 1906 ng * h/mL and a half-life of 0.66 h.",Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17204950/),h,0.66,72461,DB00448,Lansoprazole
,18937302,flow rate,"Chromatographic separation was achieved with 0.01 M ammonium acetate:acetonitrile (40:60, v/v) at a flow rate of 0.25 mL/min on an Inertsil ODS 3 column with a total run time 2.5 min.",Highly sensitive method for the determination of omeprazole in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18937302/),[ml] / [min],0.25,74387,DB00448,Lansoprazole
,18937302,total run time,"Chromatographic separation was achieved with 0.01 M ammonium acetate:acetonitrile (40:60, v/v) at a flow rate of 0.25 mL/min on an Inertsil ODS 3 column with a total run time 2.5 min.",Highly sensitive method for the determination of omeprazole in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18937302/),min,2.5,74388,DB00448,Lansoprazole
,18937302,ion transitions,The MS/MS ion transitions monitored were 346.1 --> 198.1 for OPZ and 370.1 --> 252.1 for IS.,Highly sensitive method for the determination of omeprazole in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18937302/),,346.1,74389,DB00448,Lansoprazole
,18937302,ion transitions,The MS/MS ion transitions monitored were 346.1 --> 198.1 for OPZ and 370.1 --> 252.1 for IS.,Highly sensitive method for the determination of omeprazole in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18937302/),,198.1,74390,DB00448,Lansoprazole
,18937302,ion transitions,The MS/MS ion transitions monitored were 346.1 --> 198.1 for OPZ and 370.1 --> 252.1 for IS.,Highly sensitive method for the determination of omeprazole in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18937302/),,370.1,74391,DB00448,Lansoprazole
,18937302,ion transitions,The MS/MS ion transitions monitored were 346.1 --> 198.1 for OPZ and 370.1 --> 252.1 for IS.,Highly sensitive method for the determination of omeprazole in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18937302/),,252.1,74392,DB00448,Lansoprazole
,24683233,Cmax,"The mean (SD) pharmacokinetic properties of lansoprazole were as follows: Cmax, 1047 (344) ng/mL; Tmax, 2.0 (0.7) hours; t½z, 2.24 (1.43) hours; MRT, 3.62 (0.87) hours; AUC0-24, 3388 (1484) ng/mL/h; AUC0-∞, 3496 (1693) ng/mL/h; CLz/F, 9.96 (3.74) L/h; and Vz/F, 32.83 (11.74) L.","Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683233/),[ng] / [ml],1047,74640,DB00448,Lansoprazole
,24683233,Tmax,"The mean (SD) pharmacokinetic properties of lansoprazole were as follows: Cmax, 1047 (344) ng/mL; Tmax, 2.0 (0.7) hours; t½z, 2.24 (1.43) hours; MRT, 3.62 (0.87) hours; AUC0-24, 3388 (1484) ng/mL/h; AUC0-∞, 3496 (1693) ng/mL/h; CLz/F, 9.96 (3.74) L/h; and Vz/F, 32.83 (11.74) L.","Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683233/),h,2.0,74641,DB00448,Lansoprazole
,24683233,t½z,"The mean (SD) pharmacokinetic properties of lansoprazole were as follows: Cmax, 1047 (344) ng/mL; Tmax, 2.0 (0.7) hours; t½z, 2.24 (1.43) hours; MRT, 3.62 (0.87) hours; AUC0-24, 3388 (1484) ng/mL/h; AUC0-∞, 3496 (1693) ng/mL/h; CLz/F, 9.96 (3.74) L/h; and Vz/F, 32.83 (11.74) L.","Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683233/),h,2.24,74642,DB00448,Lansoprazole
,24683233,MRT,"The mean (SD) pharmacokinetic properties of lansoprazole were as follows: Cmax, 1047 (344) ng/mL; Tmax, 2.0 (0.7) hours; t½z, 2.24 (1.43) hours; MRT, 3.62 (0.87) hours; AUC0-24, 3388 (1484) ng/mL/h; AUC0-∞, 3496 (1693) ng/mL/h; CLz/F, 9.96 (3.74) L/h; and Vz/F, 32.83 (11.74) L.","Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683233/),h,3.62,74643,DB00448,Lansoprazole
,24683233,AUC0-24,"The mean (SD) pharmacokinetic properties of lansoprazole were as follows: Cmax, 1047 (344) ng/mL; Tmax, 2.0 (0.7) hours; t½z, 2.24 (1.43) hours; MRT, 3.62 (0.87) hours; AUC0-24, 3388 (1484) ng/mL/h; AUC0-∞, 3496 (1693) ng/mL/h; CLz/F, 9.96 (3.74) L/h; and Vz/F, 32.83 (11.74) L.","Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683233/),[ng] / [h·ml],3388,74644,DB00448,Lansoprazole
,24683233,AUC0-∞,"The mean (SD) pharmacokinetic properties of lansoprazole were as follows: Cmax, 1047 (344) ng/mL; Tmax, 2.0 (0.7) hours; t½z, 2.24 (1.43) hours; MRT, 3.62 (0.87) hours; AUC0-24, 3388 (1484) ng/mL/h; AUC0-∞, 3496 (1693) ng/mL/h; CLz/F, 9.96 (3.74) L/h; and Vz/F, 32.83 (11.74) L.","Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683233/),[ng] / [h·ml],3496,74645,DB00448,Lansoprazole
,24683233,CLz/F,"The mean (SD) pharmacokinetic properties of lansoprazole were as follows: Cmax, 1047 (344) ng/mL; Tmax, 2.0 (0.7) hours; t½z, 2.24 (1.43) hours; MRT, 3.62 (0.87) hours; AUC0-24, 3388 (1484) ng/mL/h; AUC0-∞, 3496 (1693) ng/mL/h; CLz/F, 9.96 (3.74) L/h; and Vz/F, 32.83 (11.74) L.","Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683233/),[l] / [h],9.96,74646,DB00448,Lansoprazole
,24683233,Vz/F,"The mean (SD) pharmacokinetic properties of lansoprazole were as follows: Cmax, 1047 (344) ng/mL; Tmax, 2.0 (0.7) hours; t½z, 2.24 (1.43) hours; MRT, 3.62 (0.87) hours; AUC0-24, 3388 (1484) ng/mL/h; AUC0-∞, 3496 (1693) ng/mL/h; CLz/F, 9.96 (3.74) L/h; and Vz/F, 32.83 (11.74) L.","Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683233/),l,32.83,74647,DB00448,Lansoprazole
,24683233,Cmax,"The findings with 5'-hydroxy lansoprazole and lansoprazole sulfone, respectively, were as follows: Cmax, 111.2 (41.8) and 66.6 (52.9) ng/mL; Tmax, 2.1 (0.8) and 1.9 (0.8) hours; t½z, 2.31 (1.18) and 2.52 (1.54) hours; and AUC0-24, 317.0 (81.2) and 231.9 (241.7) ng/mL/h.","Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683233/),[ng] / [ml],111.2,74648,DB00448,Lansoprazole
,24683233,Cmax,"The findings with 5'-hydroxy lansoprazole and lansoprazole sulfone, respectively, were as follows: Cmax, 111.2 (41.8) and 66.6 (52.9) ng/mL; Tmax, 2.1 (0.8) and 1.9 (0.8) hours; t½z, 2.31 (1.18) and 2.52 (1.54) hours; and AUC0-24, 317.0 (81.2) and 231.9 (241.7) ng/mL/h.","Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683233/),[ng] / [ml],66.6,74649,DB00448,Lansoprazole
,24683233,Tmax,"The findings with 5'-hydroxy lansoprazole and lansoprazole sulfone, respectively, were as follows: Cmax, 111.2 (41.8) and 66.6 (52.9) ng/mL; Tmax, 2.1 (0.8) and 1.9 (0.8) hours; t½z, 2.31 (1.18) and 2.52 (1.54) hours; and AUC0-24, 317.0 (81.2) and 231.9 (241.7) ng/mL/h.","Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683233/),h,2.1,74650,DB00448,Lansoprazole
,24683233,Tmax,"The findings with 5'-hydroxy lansoprazole and lansoprazole sulfone, respectively, were as follows: Cmax, 111.2 (41.8) and 66.6 (52.9) ng/mL; Tmax, 2.1 (0.8) and 1.9 (0.8) hours; t½z, 2.31 (1.18) and 2.52 (1.54) hours; and AUC0-24, 317.0 (81.2) and 231.9 (241.7) ng/mL/h.","Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683233/),h,1.9,74651,DB00448,Lansoprazole
,24683233,t½z,"The findings with 5'-hydroxy lansoprazole and lansoprazole sulfone, respectively, were as follows: Cmax, 111.2 (41.8) and 66.6 (52.9) ng/mL; Tmax, 2.1 (0.8) and 1.9 (0.8) hours; t½z, 2.31 (1.18) and 2.52 (1.54) hours; and AUC0-24, 317.0 (81.2) and 231.9 (241.7) ng/mL/h.","Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683233/),h,2.31,74652,DB00448,Lansoprazole
,24683233,t½z,"The findings with 5'-hydroxy lansoprazole and lansoprazole sulfone, respectively, were as follows: Cmax, 111.2 (41.8) and 66.6 (52.9) ng/mL; Tmax, 2.1 (0.8) and 1.9 (0.8) hours; t½z, 2.31 (1.18) and 2.52 (1.54) hours; and AUC0-24, 317.0 (81.2) and 231.9 (241.7) ng/mL/h.","Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683233/),h,2.52,74653,DB00448,Lansoprazole
,24683233,AUC0-24,"The findings with 5'-hydroxy lansoprazole and lansoprazole sulfone, respectively, were as follows: Cmax, 111.2 (41.8) and 66.6 (52.9) ng/mL; Tmax, 2.1 (0.8) and 1.9 (0.8) hours; t½z, 2.31 (1.18) and 2.52 (1.54) hours; and AUC0-24, 317.0 (81.2) and 231.9 (241.7) ng/mL/h.","Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683233/),[ng] / [h·ml],317.0,74654,DB00448,Lansoprazole
,24683233,AUC0-24,"The findings with 5'-hydroxy lansoprazole and lansoprazole sulfone, respectively, were as follows: Cmax, 111.2 (41.8) and 66.6 (52.9) ng/mL; Tmax, 2.1 (0.8) and 1.9 (0.8) hours; t½z, 2.31 (1.18) and 2.52 (1.54) hours; and AUC0-24, 317.0 (81.2) and 231.9 (241.7) ng/mL/h.","Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683233/),[ng] / [h·ml],231.9,74655,DB00448,Lansoprazole
,24683233,Cmax,"In these healthy Chinese male volunteers administered a single oral dose of lansoprazole 30 mg, absorption of lansoprazole was rapid (mean Cmax, 1047 ng/mL; Tmax, ~2.0 hours).","Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683233/),[ng] / [ml],1047,74656,DB00448,Lansoprazole
,24683233,Tmax,"In these healthy Chinese male volunteers administered a single oral dose of lansoprazole 30 mg, absorption of lansoprazole was rapid (mean Cmax, 1047 ng/mL; Tmax, ~2.0 hours).","Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683233/),h,2.0,74657,DB00448,Lansoprazole
,24683233,Cmax,"Its 2 primary active metabolites, 5'-hydroxy lansoprazole and lansoprazole sulfone, were identified in measurable quantities in plasma (Cmax, 111.2 and 66.6 ng/mL, respectively; and Tmax, 2.1 and 1.9 hours).","Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683233/),[ng] / [ml],111.2,74658,DB00448,Lansoprazole
,24683233,Cmax,"Its 2 primary active metabolites, 5'-hydroxy lansoprazole and lansoprazole sulfone, were identified in measurable quantities in plasma (Cmax, 111.2 and 66.6 ng/mL, respectively; and Tmax, 2.1 and 1.9 hours).","Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683233/),[ng] / [ml],66.6,74659,DB00448,Lansoprazole
,24683233,Tmax,"Its 2 primary active metabolites, 5'-hydroxy lansoprazole and lansoprazole sulfone, were identified in measurable quantities in plasma (Cmax, 111.2 and 66.6 ng/mL, respectively; and Tmax, 2.1 and 1.9 hours).","Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683233/),h,2.1,74660,DB00448,Lansoprazole
,24683233,Tmax,"Its 2 primary active metabolites, 5'-hydroxy lansoprazole and lansoprazole sulfone, were identified in measurable quantities in plasma (Cmax, 111.2 and 66.6 ng/mL, respectively; and Tmax, 2.1 and 1.9 hours).","Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683233/),h,1.9,74661,DB00448,Lansoprazole
,24683233,t½z,"The plasma t½z did not appear to reflect the duration of suppression of gastric acid secretion: the t½z values of lansoprazole and the 2 metabolites were ~2 to 2.5 hours, while the acid-inhibitory effect lasted >24 hours.","Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24683233/),h,2 to 2.5,74662,DB00448,Lansoprazole
,24170325,elimination half-life,"Moreover, lansoprazole prolonged the metformin elimination half-life from 3.9 to 4.5 h and decreased its renal clearance by 13 % (P < 0.05).","The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24170325/),h,3,76686,DB00448,Lansoprazole
,9877309,metabolic ratio,The in-vitro metabolic study showed that the mean metabolic ratio (45.9%) for (-)-lansoprazole was significantly greater than that (19.8%) for the (+) enantiomer in rat liver microsomes at 5.6 microM lansoprazole.,Pharmacokinetic differences between lansoprazole enantiomers in rats. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9877309/),,45,87735,DB00448,Lansoprazole
,9877309,metabolic ratio,The in-vitro metabolic study showed that the mean metabolic ratio (45.9%) for (-)-lansoprazole was significantly greater than that (19.8%) for the (+) enantiomer in rat liver microsomes at 5.6 microM lansoprazole.,Pharmacokinetic differences between lansoprazole enantiomers in rats. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9877309/),,19,87736,DB00448,Lansoprazole
,26369775,plasma protein binding,The plasma protein binding of vonoprazan is 80% in healthy subjects.,"The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26369775/),%,80,92503,DB00448,Lansoprazole
,26369775,apparent volume of distribution,It distributes extensively into tissues with a mean apparent volume of distribution of 1050 L.,"The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26369775/),l,1050,92504,DB00448,Lansoprazole
,26369775,pKa,"Being a base with pKa of 9.6 and with acid-resistant properties, vonoprazan is highly concentrated in the acidic canaliculi of the gastric parietal cells and elicited an acid suppression effect for longer than 24 h after the administration of 20 mg.","The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26369775/),,9.6,92505,DB00448,Lansoprazole
,26369775,apparent terminal half-life,The mean apparent terminal half-life of the drug is approximately 7.7 h in healthy adults.,"The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26369775/),h,7.7,92506,DB00448,Lansoprazole
,26369775,pH >4 holding time ratios,"During repeated dosing of 20 mg once daily, the 24-h intragastric pH >4 holding time ratios were 63 and 83 % on days 1 and 7, respectively.","The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26369775/),%,63,92507,DB00448,Lansoprazole
,26369775,pH >4 holding time ratios,"During repeated dosing of 20 mg once daily, the 24-h intragastric pH >4 holding time ratios were 63 and 83 % on days 1 and 7, respectively.","The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26369775/),%,83,92508,DB00448,Lansoprazole
,21618562,total run time,The total run time was 2.00 min and the elution of DEX and IS occurred at 1.20 min.,Development and validation of a highly sensitive LC-MS/MS method for quantitation of dexlansoprazole in human plasma: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21618562/),min,2.00,93251,DB00448,Lansoprazole
,21618562,flow rate,"This was achieved with a mobile phase consisting of 0.2% ammonia-acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on an X-terra RP 18 (50 × 4.6 mm, 5 µm) column.",Development and validation of a highly sensitive LC-MS/MS method for quantitation of dexlansoprazole in human plasma: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21618562/),[ml] / [min],0.50,93252,DB00448,Lansoprazole
,15823771,C(max),"The mean (SD) values for C(max) and AUC from time 0 to infinity (AUC(0-infinity) for the lansoprazole 15-mg sachet (591.9 [242.3] ng/mL and 1614 [2065] ng.h/mL, respectively) did not differ significantly from those for the lansoprazole 15-mg capsules (578.6 [275.2] ng/mL and 1620 [2290] ng.h/mL, respectively).",Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823771/),[ng] / [ml],591.9,96782,DB00448,Lansoprazole
,15823771,C(max),"The mean (SD) values for C(max) and AUC from time 0 to infinity (AUC(0-infinity) for the lansoprazole 15-mg sachet (591.9 [242.3] ng/mL and 1614 [2065] ng.h/mL, respectively) did not differ significantly from those for the lansoprazole 15-mg capsules (578.6 [275.2] ng/mL and 1620 [2290] ng.h/mL, respectively).",Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823771/),[ng] / [ml],578.6,96783,DB00448,Lansoprazole
,15823771,AUC from time 0 to infinity (AUC(0-infinity),"The mean (SD) values for C(max) and AUC from time 0 to infinity (AUC(0-infinity) for the lansoprazole 15-mg sachet (591.9 [242.3] ng/mL and 1614 [2065] ng.h/mL, respectively) did not differ significantly from those for the lansoprazole 15-mg capsules (578.6 [275.2] ng/mL and 1620 [2290] ng.h/mL, respectively).",Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823771/),[h·ng] / [ml],1614,96784,DB00448,Lansoprazole
,15823771,AUC from time 0 to infinity (AUC(0-infinity),"The mean (SD) values for C(max) and AUC from time 0 to infinity (AUC(0-infinity) for the lansoprazole 15-mg sachet (591.9 [242.3] ng/mL and 1614 [2065] ng.h/mL, respectively) did not differ significantly from those for the lansoprazole 15-mg capsules (578.6 [275.2] ng/mL and 1620 [2290] ng.h/mL, respectively).",Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823771/),[h·ng] / [ml],1620,96785,DB00448,Lansoprazole
,15823771,C(max),"These parameters also did not differ significantly between the lansoprazole 30-mg sachet and 30-mg capsule: mean (SD) C(max), 1103 (428.3) and 1077 (465.6) ng/mL, respectively; mean (SD) AUC(0-infinity), 2655 (1338) and 2669 (1311) ng.h/mL, respectively.",Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823771/),[ng] / [ml],1103,96786,DB00448,Lansoprazole
,15823771,C(max),"These parameters also did not differ significantly between the lansoprazole 30-mg sachet and 30-mg capsule: mean (SD) C(max), 1103 (428.3) and 1077 (465.6) ng/mL, respectively; mean (SD) AUC(0-infinity), 2655 (1338) and 2669 (1311) ng.h/mL, respectively.",Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823771/),[ng] / [ml],1077,96787,DB00448,Lansoprazole
,15823771,AUC(0-infinity),"These parameters also did not differ significantly between the lansoprazole 30-mg sachet and 30-mg capsule: mean (SD) C(max), 1103 (428.3) and 1077 (465.6) ng/mL, respectively; mean (SD) AUC(0-infinity), 2655 (1338) and 2669 (1311) ng.h/mL, respectively.",Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823771/),[h·ng] / [ml],2655,96788,DB00448,Lansoprazole
,15823771,AUC(0-infinity),"These parameters also did not differ significantly between the lansoprazole 30-mg sachet and 30-mg capsule: mean (SD) C(max), 1103 (428.3) and 1077 (465.6) ng/mL, respectively; mean (SD) AUC(0-infinity), 2655 (1338) and 2669 (1311) ng.h/mL, respectively.",Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823771/),[h·ng] / [ml],2669,96789,DB00448,Lansoprazole
,11269565,gastric ion concentration,"The predicted mean gastric ion concentration was 23.2 mM (pH 1.6) with the peak time at 12.6 hours (8:30 p.m.), and the half-time for H+ removal from the stomach averaged 1.7 hours.",Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269565/),mM,23.2,97277,DB00448,Lansoprazole
,11269565,half-time,"The predicted mean gastric ion concentration was 23.2 mM (pH 1.6) with the peak time at 12.6 hours (8:30 p.m.), and the half-time for H+ removal from the stomach averaged 1.7 hours.",Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269565/),h,1.7,97278,DB00448,Lansoprazole
,11269565,half-life of gastric food removal,The estimated half-life of gastric food removal was 0.8 hours.,Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269565/),h,0.8,97279,DB00448,Lansoprazole
,11269565,rate constant,The rate constant for normal H+/K+-ATPase degradation was 0.045 h(-1).,Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269565/),1/[h],0.045,97280,DB00448,Lansoprazole
,11269565,second-order enzyme inactivation constant,"The pharmacodynamic parameter describing lansoprazole action on gastric acid secretion was the second-order enzyme inactivation constant, which averaged 0.16 microg(-1) x L x h(-1).",Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269565/),[l] / [h·μg],0.16,97281,DB00448,Lansoprazole
,11136283,terminal disposition half-life,Lansoprazole's terminal disposition half-life was 1.11 h.,Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11136283/),h,1.11,98778,DB00448,Lansoprazole
,11136283,half-lives,"Mean pH and serum gastrin returned to baseline with half-lives of 22 and 19 h, respectively.",Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11136283/),h,22,98779,DB00448,Lansoprazole
,11136283,half-lives,"Mean pH and serum gastrin returned to baseline with half-lives of 22 and 19 h, respectively.",Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11136283/),h,19,98780,DB00448,Lansoprazole
,12562448,Tmax,"Tmax occurred at 1.8 and 2.0 h with the 15-mg and 30-mg tablets, respectively.",Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12562448/),h,1.8,100191,DB00448,Lansoprazole
,12562448,Tmax,"Tmax occurred at 1.8 and 2.0 h with the 15-mg and 30-mg tablets, respectively.",Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12562448/),h,2.0,100192,DB00448,Lansoprazole
,12562448,terminal elimination half-lives (t1/2),The terminal elimination half-lives (t1/2) were identical in both dose groups (1.18 h).,Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12562448/),h,1.18,100193,DB00448,Lansoprazole
,21802143,Drug Interaction Probability Score,"The calculated Drug Interaction Probability Score between TAC and LAN was 6, indicating a probable interaction.",Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21802143/),,6,101788,DB00448,Lansoprazole
,12959285,CL0,"The mean clearance and elimination half-life of lansoprazole were about 40% lower and higher, respectively, in the older subjects (CL0: 12-14 vs 20-24 1 h(-1); t1/2,z: 1.90-2.19 vs 1.26-1.44 h).",Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959285/),[1] / [h],12-14,105028,DB00448,Lansoprazole
,12959285,CL0,"The mean clearance and elimination half-life of lansoprazole were about 40% lower and higher, respectively, in the older subjects (CL0: 12-14 vs 20-24 1 h(-1); t1/2,z: 1.90-2.19 vs 1.26-1.44 h).",Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959285/),[1] / [h],20-24,105029,DB00448,Lansoprazole
,12959285,"t1/2,z","The mean clearance and elimination half-life of lansoprazole were about 40% lower and higher, respectively, in the older subjects (CL0: 12-14 vs 20-24 1 h(-1); t1/2,z: 1.90-2.19 vs 1.26-1.44 h).",Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959285/),h,1.90-2.19,105030,DB00448,Lansoprazole
,12959285,"t1/2,z","The mean clearance and elimination half-life of lansoprazole were about 40% lower and higher, respectively, in the older subjects (CL0: 12-14 vs 20-24 1 h(-1); t1/2,z: 1.90-2.19 vs 1.26-1.44 h).",Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959285/),h,1.26-1.44,105031,DB00448,Lansoprazole
,12959285,AUC,"However, the AUC associated with a 50% decrease in acid secretion was similar (849 vs 892 ng ml(-1) h) for both age groups.",Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959285/),[h·ng] / [ml],849,105032,DB00448,Lansoprazole
,12959285,AUC,"However, the AUC associated with a 50% decrease in acid secretion was similar (849 vs 892 ng ml(-1) h) for both age groups.",Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959285/),[h·ng] / [ml],892,105033,DB00448,Lansoprazole
,9200535,recovery,The recovery study of authentic analytes added to plasma at 0.05 to 0.25 microg/ml was 95.37+/-2.15% and the lowest amount of lansoprazole that could be detected was 20 ng/ml plasma.,High-performance thin-layer chromatographic method for the detection and determination of lansoprazole in human plasma and its use in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9200535/),%,95.37,105939,DB00448,Lansoprazole
,15752376,"AUC0, infinity","During placebo administration, the mean AUC0, infinity of lansoprazole in homozygous EMs, heterozygous EMs and PMs were 4652 (95% CI, 2294, 7009) ng ml(-1) h, 8299 (4784, 11814) ng ml(-1) h and 25293 (17643, 32943) ng ml(-1) h (P < 0.001), respectively.",Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752376/),[h·ng] / [ml],4652,112416,DB00448,Lansoprazole
,15752376,"AUC0, infinity","During placebo administration, the mean AUC0, infinity of lansoprazole in homozygous EMs, heterozygous EMs and PMs were 4652 (95% CI, 2294, 7009) ng ml(-1) h, 8299 (4784, 11814) ng ml(-1) h and 25293 (17643, 32943) ng ml(-1) h (P < 0.001), respectively.",Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752376/),[h·ng] / [ml],8299,112417,DB00448,Lansoprazole
,15752376,"AUC0, infinity","During placebo administration, the mean AUC0, infinity of lansoprazole in homozygous EMs, heterozygous EMs and PMs were 4652 (95% CI, 2294, 7009) ng ml(-1) h, 8299 (4784, 11814) ng ml(-1) h and 25293 (17643, 32943) ng ml(-1) h (P < 0.001), respectively.",Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752376/),[h·ng] / [ml],25293,112418,DB00448,Lansoprazole
,10391666,AUC,"The pharmacokinetics of lansoprazole were significantly different among groups; AUC values were 1.55+/-0.20 microg x h/mL in white extensive metabolizers, 7.01+/-0.72 microg x hr/mL in Korean extensive metabolizers, and 14.34+/-2.60 microg x h/mL in poor metabolizers (P < .001).",Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391666/),[h·μg] / [ml],1.55,113122,DB00448,Lansoprazole
,10391666,AUC,"The pharmacokinetics of lansoprazole were significantly different among groups; AUC values were 1.55+/-0.20 microg x h/mL in white extensive metabolizers, 7.01+/-0.72 microg x hr/mL in Korean extensive metabolizers, and 14.34+/-2.60 microg x h/mL in poor metabolizers (P < .001).",Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391666/),[h·μg] / [ml],7.01,113123,DB00448,Lansoprazole
,10391666,AUC,"The pharmacokinetics of lansoprazole were significantly different among groups; AUC values were 1.55+/-0.20 microg x h/mL in white extensive metabolizers, 7.01+/-0.72 microg x hr/mL in Korean extensive metabolizers, and 14.34+/-2.60 microg x h/mL in poor metabolizers (P < .001).",Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391666/),[h·μg] / [ml],14.34,113124,DB00448,Lansoprazole
,8299672,t1/2,"In cirrhotics tmax was prolonged, the AUC was increased (P < 0.001) and there was prolongation of t1/2 (6.1 h in CC and 7.2 h in UCC compared to 1.4 h in healthy subjects).",Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8299672/),h,6.1,118415,DB00448,Lansoprazole
,8299672,t1/2,"In cirrhotics tmax was prolonged, the AUC was increased (P < 0.001) and there was prolongation of t1/2 (6.1 h in CC and 7.2 h in UCC compared to 1.4 h in healthy subjects).",Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8299672/),h,7.2,118416,DB00448,Lansoprazole
,8299672,t1/2,"In cirrhotics tmax was prolonged, the AUC was increased (P < 0.001) and there was prolongation of t1/2 (6.1 h in CC and 7.2 h in UCC compared to 1.4 h in healthy subjects).",Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8299672/),h,1.4,118417,DB00448,Lansoprazole
,15664363,total time,"The peak was detected by a ultraviolet detector set at a wavelength of 285 nm, and the total time for a chromatographic separation was approximately 25 min.",Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664363/),min,25,125043,DB00448,Lansoprazole
,15664363,recoveries,"Mean recoveries were 74.0% for lansoprazole, 68.3% for 5-hydroxylansoprazole, and 79.4% for lansoprazole sulfone.",Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664363/),%,74.0,125044,DB00448,Lansoprazole
,15664363,recoveries,"Mean recoveries were 74.0% for lansoprazole, 68.3% for 5-hydroxylansoprazole, and 79.4% for lansoprazole sulfone.",Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664363/),%,68.3,125045,DB00448,Lansoprazole
,15664363,recoveries,"Mean recoveries were 74.0% for lansoprazole, 68.3% for 5-hydroxylansoprazole, and 79.4% for lansoprazole sulfone.",Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664363/),%,79.4,125046,DB00448,Lansoprazole
,31316654,Retention times,"Retention times of pantoprazole and internal standard, lansoprazole was 4.1 and 6.0 min respectively.",A New Solid-Phase Extraction Method for Determination of Pantoprazole in Human Plasma Using High-Performance Liquid Chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31316654/),min,4.1,135200,DB00448,Lansoprazole
,31316654,Retention times,"Retention times of pantoprazole and internal standard, lansoprazole was 4.1 and 6.0 min respectively.",A New Solid-Phase Extraction Method for Determination of Pantoprazole in Human Plasma Using High-Performance Liquid Chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31316654/),min,6.0,135201,DB00448,Lansoprazole
,31068304,recovery,"The intra-day and inter-day precisions were all less than 13%, and the recovery was between 66.50% and 82.67%; the stability of the plasma samples met the requirements of testing.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),%,66.50,135817,DB00448,Lansoprazole
,31068304,recovery,"The intra-day and inter-day precisions were all less than 13%, and the recovery was between 66.50% and 82.67%; the stability of the plasma samples met the requirements of testing.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),%,82.67,135818,DB00448,Lansoprazole
,31068304,AUC0-24 h,"The AUC0-24 h of atorvastatin in rat plasma after single and combined administration was 438.78±139.61 and 927.43±204.12 h·μg·L-1, CLz/F was 23.89±8.14 and 10.43±2.58 L·h-1·kg-1, Cmax was 149.62±131.10 and 159.37±36.83 μg/L, t1/2 was 5.08±1.63 and (5.58±2.11 h, and Tmax was 0.37±0.14 and 3.60±1.52 h, respectively; AUC0-24 h, CLZ/F and Tmax of atorvastatin in rat plasma differed significantly between single and combined administration.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),[h·μg] / [l],438.78,135819,DB00448,Lansoprazole
,31068304,AUC0-24 h,"The AUC0-24 h of atorvastatin in rat plasma after single and combined administration was 438.78±139.61 and 927.43±204.12 h·μg·L-1, CLz/F was 23.89±8.14 and 10.43±2.58 L·h-1·kg-1, Cmax was 149.62±131.10 and 159.37±36.83 μg/L, t1/2 was 5.08±1.63 and (5.58±2.11 h, and Tmax was 0.37±0.14 and 3.60±1.52 h, respectively; AUC0-24 h, CLZ/F and Tmax of atorvastatin in rat plasma differed significantly between single and combined administration.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),[h·μg] / [l],927.43,135820,DB00448,Lansoprazole
,31068304,CLz/F,"The AUC0-24 h of atorvastatin in rat plasma after single and combined administration was 438.78±139.61 and 927.43±204.12 h·μg·L-1, CLz/F was 23.89±8.14 and 10.43±2.58 L·h-1·kg-1, Cmax was 149.62±131.10 and 159.37±36.83 μg/L, t1/2 was 5.08±1.63 and (5.58±2.11 h, and Tmax was 0.37±0.14 and 3.60±1.52 h, respectively; AUC0-24 h, CLZ/F and Tmax of atorvastatin in rat plasma differed significantly between single and combined administration.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),[l] / [h·kg],23.89,135821,DB00448,Lansoprazole
,31068304,CLz/F,"The AUC0-24 h of atorvastatin in rat plasma after single and combined administration was 438.78±139.61 and 927.43±204.12 h·μg·L-1, CLz/F was 23.89±8.14 and 10.43±2.58 L·h-1·kg-1, Cmax was 149.62±131.10 and 159.37±36.83 μg/L, t1/2 was 5.08±1.63 and (5.58±2.11 h, and Tmax was 0.37±0.14 and 3.60±1.52 h, respectively; AUC0-24 h, CLZ/F and Tmax of atorvastatin in rat plasma differed significantly between single and combined administration.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),[l] / [h·kg],10.43,135822,DB00448,Lansoprazole
,31068304,Cmax,"The AUC0-24 h of atorvastatin in rat plasma after single and combined administration was 438.78±139.61 and 927.43±204.12 h·μg·L-1, CLz/F was 23.89±8.14 and 10.43±2.58 L·h-1·kg-1, Cmax was 149.62±131.10 and 159.37±36.83 μg/L, t1/2 was 5.08±1.63 and (5.58±2.11 h, and Tmax was 0.37±0.14 and 3.60±1.52 h, respectively; AUC0-24 h, CLZ/F and Tmax of atorvastatin in rat plasma differed significantly between single and combined administration.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),[μg] / [l],149.62,135823,DB00448,Lansoprazole
,31068304,Cmax,"The AUC0-24 h of atorvastatin in rat plasma after single and combined administration was 438.78±139.61 and 927.43±204.12 h·μg·L-1, CLz/F was 23.89±8.14 and 10.43±2.58 L·h-1·kg-1, Cmax was 149.62±131.10 and 159.37±36.83 μg/L, t1/2 was 5.08±1.63 and (5.58±2.11 h, and Tmax was 0.37±0.14 and 3.60±1.52 h, respectively; AUC0-24 h, CLZ/F and Tmax of atorvastatin in rat plasma differed significantly between single and combined administration.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),[μg] / [l],159.37,135824,DB00448,Lansoprazole
,31068304,t1/2,"The AUC0-24 h of atorvastatin in rat plasma after single and combined administration was 438.78±139.61 and 927.43±204.12 h·μg·L-1, CLz/F was 23.89±8.14 and 10.43±2.58 L·h-1·kg-1, Cmax was 149.62±131.10 and 159.37±36.83 μg/L, t1/2 was 5.08±1.63 and (5.58±2.11 h, and Tmax was 0.37±0.14 and 3.60±1.52 h, respectively; AUC0-24 h, CLZ/F and Tmax of atorvastatin in rat plasma differed significantly between single and combined administration.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),h,5.08,135825,DB00448,Lansoprazole
,31068304,t1/2,"The AUC0-24 h of atorvastatin in rat plasma after single and combined administration was 438.78±139.61 and 927.43±204.12 h·μg·L-1, CLz/F was 23.89±8.14 and 10.43±2.58 L·h-1·kg-1, Cmax was 149.62±131.10 and 159.37±36.83 μg/L, t1/2 was 5.08±1.63 and (5.58±2.11 h, and Tmax was 0.37±0.14 and 3.60±1.52 h, respectively; AUC0-24 h, CLZ/F and Tmax of atorvastatin in rat plasma differed significantly between single and combined administration.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),h,5.58,135826,DB00448,Lansoprazole
,31068304,Tmax,"The AUC0-24 h of atorvastatin in rat plasma after single and combined administration was 438.78±139.61 and 927.43±204.12 h·μg·L-1, CLz/F was 23.89±8.14 and 10.43±2.58 L·h-1·kg-1, Cmax was 149.62±131.10 and 159.37±36.83 μg/L, t1/2 was 5.08±1.63 and (5.58±2.11 h, and Tmax was 0.37±0.14 and 3.60±1.52 h, respectively; AUC0-24 h, CLZ/F and Tmax of atorvastatin in rat plasma differed significantly between single and combined administration.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),h,0.37,135827,DB00448,Lansoprazole
,31068304,Tmax,"The AUC0-24 h of atorvastatin in rat plasma after single and combined administration was 438.78±139.61 and 927.43±204.12 h·μg·L-1, CLz/F was 23.89±8.14 and 10.43±2.58 L·h-1·kg-1, Cmax was 149.62±131.10 and 159.37±36.83 μg/L, t1/2 was 5.08±1.63 and (5.58±2.11 h, and Tmax was 0.37±0.14 and 3.60±1.52 h, respectively; AUC0-24 h, CLZ/F and Tmax of atorvastatin in rat plasma differed significantly between single and combined administration.",[Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31068304/),h,3.60,135828,DB00448,Lansoprazole
,9725501,retention time,The retention time was 5.2 min for niflumic acid and 6.7 min for lansoprazole.,Determination of lansoprazole in biological fluids and pharmaceutical dosage by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725501/),min,5.2,135848,DB00448,Lansoprazole
,9725501,retention time,The retention time was 5.2 min for niflumic acid and 6.7 min for lansoprazole.,Determination of lansoprazole in biological fluids and pharmaceutical dosage by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725501/),min,6.7,135849,DB00448,Lansoprazole
,9725501,detection limit,The detection limit was 20 ng/ml using a 100 microl loop.,Determination of lansoprazole in biological fluids and pharmaceutical dosage by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725501/),[ng] / [ml],20,135850,DB00448,Lansoprazole
,15951475,relative bioavailability,DP relative bioavailability was reduced 53% with conventional tablets compared to the composite buffered ER capsule in reduced gastric acid conditions.,Dipyridamole bioavailability in subjects with reduced gastric acidity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15951475/),%,53,136569,DB00448,Lansoprazole
,21769476,T(max),"In the homEM and in the hetEM groups, the main kinetic parameters were as follows: T(max) (2.1875 ± 0.777) and (2.54 ± 1.87) h, C(max) (697.875 ± 335) and (833.58 ± 436.26) mg/l, t(1/2) (1.3 ± 0.43) and (2.38 ± 1.64) h, AUC((0→∞)) were (1,684.9 ± 888) and (3,609.8 ± 318) mg h l(-1), respectively.",Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21769476/),h,2.1875,140095,DB00448,Lansoprazole
,21769476,T(max),"In the homEM and in the hetEM groups, the main kinetic parameters were as follows: T(max) (2.1875 ± 0.777) and (2.54 ± 1.87) h, C(max) (697.875 ± 335) and (833.58 ± 436.26) mg/l, t(1/2) (1.3 ± 0.43) and (2.38 ± 1.64) h, AUC((0→∞)) were (1,684.9 ± 888) and (3,609.8 ± 318) mg h l(-1), respectively.",Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21769476/),h,2.54,140096,DB00448,Lansoprazole
,21769476,C(max),"In the homEM and in the hetEM groups, the main kinetic parameters were as follows: T(max) (2.1875 ± 0.777) and (2.54 ± 1.87) h, C(max) (697.875 ± 335) and (833.58 ± 436.26) mg/l, t(1/2) (1.3 ± 0.43) and (2.38 ± 1.64) h, AUC((0→∞)) were (1,684.9 ± 888) and (3,609.8 ± 318) mg h l(-1), respectively.",Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21769476/),[mg] / [l],697.875,140097,DB00448,Lansoprazole
,21769476,C(max),"In the homEM and in the hetEM groups, the main kinetic parameters were as follows: T(max) (2.1875 ± 0.777) and (2.54 ± 1.87) h, C(max) (697.875 ± 335) and (833.58 ± 436.26) mg/l, t(1/2) (1.3 ± 0.43) and (2.38 ± 1.64) h, AUC((0→∞)) were (1,684.9 ± 888) and (3,609.8 ± 318) mg h l(-1), respectively.",Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21769476/),[mg] / [l],833.58,140098,DB00448,Lansoprazole
,21769476,t(1/2),"In the homEM and in the hetEM groups, the main kinetic parameters were as follows: T(max) (2.1875 ± 0.777) and (2.54 ± 1.87) h, C(max) (697.875 ± 335) and (833.58 ± 436.26) mg/l, t(1/2) (1.3 ± 0.43) and (2.38 ± 1.64) h, AUC((0→∞)) were (1,684.9 ± 888) and (3,609.8 ± 318) mg h l(-1), respectively.",Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21769476/),h,1.3,140099,DB00448,Lansoprazole
,21769476,t(1/2),"In the homEM and in the hetEM groups, the main kinetic parameters were as follows: T(max) (2.1875 ± 0.777) and (2.54 ± 1.87) h, C(max) (697.875 ± 335) and (833.58 ± 436.26) mg/l, t(1/2) (1.3 ± 0.43) and (2.38 ± 1.64) h, AUC((0→∞)) were (1,684.9 ± 888) and (3,609.8 ± 318) mg h l(-1), respectively.",Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21769476/),h,2.38,140100,DB00448,Lansoprazole
,21769476,AUC((0→∞)),"In the homEM and in the hetEM groups, the main kinetic parameters were as follows: T(max) (2.1875 ± 0.777) and (2.54 ± 1.87) h, C(max) (697.875 ± 335) and (833.58 ± 436.26) mg/l, t(1/2) (1.3 ± 0.43) and (2.38 ± 1.64) h, AUC((0→∞)) were (1,684.9 ± 888) and (3,609.8 ± 318) mg h l(-1), respectively.",Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21769476/),[h·mg] / [l],"1,684.9",140101,DB00448,Lansoprazole
,21769476,AUC((0→∞)),"In the homEM and in the hetEM groups, the main kinetic parameters were as follows: T(max) (2.1875 ± 0.777) and (2.54 ± 1.87) h, C(max) (697.875 ± 335) and (833.58 ± 436.26) mg/l, t(1/2) (1.3 ± 0.43) and (2.38 ± 1.64) h, AUC((0→∞)) were (1,684.9 ± 888) and (3,609.8 ± 318) mg h l(-1), respectively.",Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21769476/),[h·mg] / [l],"3,609.8",140102,DB00448,Lansoprazole
,18590345,maximum plasma concentrations (C(max)),"After a single dose in neonates, the mean maximum plasma concentrations (C(max)) were 831 and 1672 ng/mL, and the mean area under the plasma concentration-time curve (AUC) values were 5086 and 9372 ng . h/mL for lansoprazole doses of 0.5 and 1.0 mg/kg, respectively.",Age-dependent pharmacokinetics of lansoprazole in neonates and infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18590345/),[ng] / [ml],831,141306,DB00448,Lansoprazole
,18590345,maximum plasma concentrations (C(max)),"After a single dose in neonates, the mean maximum plasma concentrations (C(max)) were 831 and 1672 ng/mL, and the mean area under the plasma concentration-time curve (AUC) values were 5086 and 9372 ng . h/mL for lansoprazole doses of 0.5 and 1.0 mg/kg, respectively.",Age-dependent pharmacokinetics of lansoprazole in neonates and infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18590345/),[ng] / [ml],1672,141307,DB00448,Lansoprazole
,18590345,area under the plasma concentration-time curve (AUC),"After a single dose in neonates, the mean maximum plasma concentrations (C(max)) were 831 and 1672 ng/mL, and the mean area under the plasma concentration-time curve (AUC) values were 5086 and 9372 ng . h/mL for lansoprazole doses of 0.5 and 1.0 mg/kg, respectively.",Age-dependent pharmacokinetics of lansoprazole in neonates and infants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18590345/),[h·ng] / [ml],5086,141308,DB00448,Lansoprazole
,18590345,area under the plasma concentration-time curve (AUC),"After a single dose in neonates, the mean maximum plasma concentrations (C(max)) were 831 and 1672 ng/mL, and the mean area under the plasma concentration-time curve (AUC) values were 5086 and 9372 ng . h/mL for lansoprazole doses of 0.5 and 1.0 mg/kg, respectively.",Age-dependent pharmacokinetics of lansoprazole in neonates and infants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18590345/),[h·ng] / [ml],9372,141309,DB00448,Lansoprazole
,18590345,time to C(max) (t(max)),The time to C(max) (t(max)) [3.1 hours] and harmonic mean terminal elimination half-life (t((1/2))) [2.8 hours] were slightly longer in neonates receiving 0.5 mg/kg than the t(max) (2.6 hours) and t((1/2)) (2.0 hours) values observed in neonates receiving 1.0 mg/kg.,Age-dependent pharmacokinetics of lansoprazole in neonates and infants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18590345/),h,3.1,141310,DB00448,Lansoprazole
,18590345,terminal elimination half-life (t((1/2))),The time to C(max) (t(max)) [3.1 hours] and harmonic mean terminal elimination half-life (t((1/2))) [2.8 hours] were slightly longer in neonates receiving 0.5 mg/kg than the t(max) (2.6 hours) and t((1/2)) (2.0 hours) values observed in neonates receiving 1.0 mg/kg.,Age-dependent pharmacokinetics of lansoprazole in neonates and infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18590345/),h,2.8,141311,DB00448,Lansoprazole
,18590345,t(max),The time to C(max) (t(max)) [3.1 hours] and harmonic mean terminal elimination half-life (t((1/2))) [2.8 hours] were slightly longer in neonates receiving 0.5 mg/kg than the t(max) (2.6 hours) and t((1/2)) (2.0 hours) values observed in neonates receiving 1.0 mg/kg.,Age-dependent pharmacokinetics of lansoprazole in neonates and infants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18590345/),h,2.6,141312,DB00448,Lansoprazole
,18590345,t((1/2)),The time to C(max) (t(max)) [3.1 hours] and harmonic mean terminal elimination half-life (t((1/2))) [2.8 hours] were slightly longer in neonates receiving 0.5 mg/kg than the t(max) (2.6 hours) and t((1/2)) (2.0 hours) values observed in neonates receiving 1.0 mg/kg.,Age-dependent pharmacokinetics of lansoprazole in neonates and infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18590345/),h,2.0,141313,DB00448,Lansoprazole
,18590345,oral clearance (CL/F),Mean oral clearance (CL/F) was identical for the two doses (0.16 L/h/kg).,Age-dependent pharmacokinetics of lansoprazole in neonates and infants. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18590345/),[l] / [h·kg],0.16,141314,DB00448,Lansoprazole
,18590345,C(max),"After a single 1.0 or 2.0 mg/kg dose in infants, the lansoprazole C(max) values were 959 and 2087 ng/mL and the mean AUC values were approximately 2203 and 5794 ng . h/mL, respectively.",Age-dependent pharmacokinetics of lansoprazole in neonates and infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18590345/),[ng] / [ml],959,141315,DB00448,Lansoprazole
,18590345,C(max),"After a single 1.0 or 2.0 mg/kg dose in infants, the lansoprazole C(max) values were 959 and 2087 ng/mL and the mean AUC values were approximately 2203 and 5794 ng . h/mL, respectively.",Age-dependent pharmacokinetics of lansoprazole in neonates and infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18590345/),[ng] / [ml],2087,141316,DB00448,Lansoprazole
,18590345,AUC,"After a single 1.0 or 2.0 mg/kg dose in infants, the lansoprazole C(max) values were 959 and 2087 ng/mL and the mean AUC values were approximately 2203 and 5794 ng . h/mL, respectively.",Age-dependent pharmacokinetics of lansoprazole in neonates and infants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18590345/),[h·ng] / [ml],2203,141317,DB00448,Lansoprazole
,18590345,AUC,"After a single 1.0 or 2.0 mg/kg dose in infants, the lansoprazole C(max) values were 959 and 2087 ng/mL and the mean AUC values were approximately 2203 and 5794 ng . h/mL, respectively.",Age-dependent pharmacokinetics of lansoprazole in neonates and infants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18590345/),[h·ng] / [ml],5794,141318,DB00448,Lansoprazole
,18590345,t(max),"The mean t(max) and mean t((1/2)) were 1.8 hours and 0.8 hours, respectively, for both doses (1.0 or 2.0 mg/kg), while mean CL/F was 0.71 and 0.61 L/h/kg, respectively.",Age-dependent pharmacokinetics of lansoprazole in neonates and infants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18590345/),h,1.8,141319,DB00448,Lansoprazole
,18590345,t((1/2)),"The mean t(max) and mean t((1/2)) were 1.8 hours and 0.8 hours, respectively, for both doses (1.0 or 2.0 mg/kg), while mean CL/F was 0.71 and 0.61 L/h/kg, respectively.",Age-dependent pharmacokinetics of lansoprazole in neonates and infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18590345/),h,0.8,141320,DB00448,Lansoprazole
,18590345,CL/F,"The mean t(max) and mean t((1/2)) were 1.8 hours and 0.8 hours, respectively, for both doses (1.0 or 2.0 mg/kg), while mean CL/F was 0.71 and 0.61 L/h/kg, respectively.",Age-dependent pharmacokinetics of lansoprazole in neonates and infants. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18590345/),[l] / [h·kg],0.71,141321,DB00448,Lansoprazole
,18590345,CL/F,"The mean t(max) and mean t((1/2)) were 1.8 hours and 0.8 hours, respectively, for both doses (1.0 or 2.0 mg/kg), while mean CL/F was 0.71 and 0.61 L/h/kg, respectively.",Age-dependent pharmacokinetics of lansoprazole in neonates and infants. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18590345/),[l] / [h·kg],0.61,141322,DB00448,Lansoprazole
,17377957,area under the plasma concentration-time curves from 0 to 12 h (AUC(0-12)),"The mean daily dose and the dose-adjusted area under the plasma concentration-time curves from 0 to 12 h (AUC(0-12)) of tacrolimus coadministered with rabeprazole or lansoprazole were the lowest and highest, respectively, in CYP2C19 poor metabolizers (PMs) having the CYP3A5*3/*3 genotype (0.084 and 0.112 mg/kg/day and 1.269 and 1.033 ng.h/ml/mg/kg, respectively).","Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17377957/),[h·ng] / [kg·mg·ml],1.269,141953,DB00448,Lansoprazole
,17377957,area under the plasma concentration-time curves from 0 to 12 h (AUC(0-12)),"The mean daily dose and the dose-adjusted area under the plasma concentration-time curves from 0 to 12 h (AUC(0-12)) of tacrolimus coadministered with rabeprazole or lansoprazole were the lowest and highest, respectively, in CYP2C19 poor metabolizers (PMs) having the CYP3A5*3/*3 genotype (0.084 and 0.112 mg/kg/day and 1.269 and 1.033 ng.h/ml/mg/kg, respectively).","Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17377957/),[h·ng] / [kg·mg·ml],1.033,141954,DB00448,Lansoprazole
,22853867,relative AUC0-12 ratio,The relative AUC0-12 ratio of lansoprazole in EMs and PMs was 1:3.3 - 4.3.,Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22853867/),,1,142475,DB00448,Lansoprazole
,1820900,limit of detection,"Lansoprazole and metabolite (sulfone (AG 1813), sulfide (AG 1777) and hydroxylated (AG 1908) metabolites) plasma concentrations were determined using a specific high pressure liquid chromatographic assay procedure, with a limit of detection of 2 ng/ml.",The effect of food and antacids on lansoprazole absorption and disposition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820900/),[ng] / [ml],2,145096,DB00448,Lansoprazole
,1820900,time to peak,"The time to peak was significantly later with food (p less than 0.001) and its magnitude was significantly decreased (600 +/- 330 ng/ml vs 1151 +/- 344 ng/ml, p less than 0.001).",The effect of food and antacids on lansoprazole absorption and disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820900/),[ng] / [ml],600,145097,DB00448,Lansoprazole
,1820900,time to peak,"The time to peak was significantly later with food (p less than 0.001) and its magnitude was significantly decreased (600 +/- 330 ng/ml vs 1151 +/- 344 ng/ml, p less than 0.001).",The effect of food and antacids on lansoprazole absorption and disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820900/),[ng] / [ml],1151,145098,DB00448,Lansoprazole
,1820900,bioavailability,"The bioavailability of lansoprazole was significantly decreased by food, about 27%, (p less than 0.05) and slightly decreased by concomitant administration of antacids (NS), the effect was more pronounced in male subjects (p less than 0.05).",The effect of food and antacids on lansoprazole absorption and disposition. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820900/),%,27,145099,DB00448,Lansoprazole
,12607793,T(max),"After lansoprazole administration, T(max) occurred at 1.6 hours in those treated with lansoprazole 15 mg and at 1.7 hours in those treated with lansoprazole 30 mg.","Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607793/),h,1.6,151641,DB00448,Lansoprazole
,12607793,T(max),"After lansoprazole administration, T(max) occurred at 1.6 hours in those treated with lansoprazole 15 mg and at 1.7 hours in those treated with lansoprazole 30 mg.","Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607793/),h,1.7,151642,DB00448,Lansoprazole
,10886044,Relative bioavailability,Relative bioavailability of omeprazole from simplified omeprazole suspension compared to the capsule was 58.4% on day 5.,Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10886044/),%,58.4,153864,DB00448,Lansoprazole
,23839484,maximum plasma concentration (C(max)),"Co-administration with lansoprazole decreased the mean maximum plasma concentration (C(max)) of bosutinib from 70.2 to 42.9 ng/mL, and the total area under the plasma concentration-time curve (AUC) from 1,940 to 1,470 ng·h/mL.",A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23839484/),[ng] / [ml],70.2,157625,DB00448,Lansoprazole
,23839484,maximum plasma concentration (C(max)),"Co-administration with lansoprazole decreased the mean maximum plasma concentration (C(max)) of bosutinib from 70.2 to 42.9 ng/mL, and the total area under the plasma concentration-time curve (AUC) from 1,940 to 1,470 ng·h/mL.",A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23839484/),[ng] / [ml],42.9,157626,DB00448,Lansoprazole
,23839484,total area under the plasma concentration-time curve (AUC),"Co-administration with lansoprazole decreased the mean maximum plasma concentration (C(max)) of bosutinib from 70.2 to 42.9 ng/mL, and the total area under the plasma concentration-time curve (AUC) from 1,940 to 1,470 ng·h/mL.",A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23839484/),[h·ng] / [ml],"1,940",157627,DB00448,Lansoprazole
,23839484,total area under the plasma concentration-time curve (AUC),"Co-administration with lansoprazole decreased the mean maximum plasma concentration (C(max)) of bosutinib from 70.2 to 42.9 ng/mL, and the total area under the plasma concentration-time curve (AUC) from 1,940 to 1,470 ng·h/mL.",A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23839484/),[h·ng] / [ml],"1,470",157628,DB00448,Lansoprazole
,23839484,apparent total body clearance,"Mean apparent total body clearance from plasma after oral administration increased from 237 to 330 L/h, and the median time to reach Cmax increased from 5 to 6 h, although this change may be related to decreased bosutinib absorption when combined with lansoprazole.",A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23839484/),[l] / [h],237 to 330,157629,DB00448,Lansoprazole
,23839484,time to reach Cmax,"Mean apparent total body clearance from plasma after oral administration increased from 237 to 330 L/h, and the median time to reach Cmax increased from 5 to 6 h, although this change may be related to decreased bosutinib absorption when combined with lansoprazole.",A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23839484/),h,5,157630,DB00448,Lansoprazole
,10807427,cure rate,"The cure rate for the peptic ulcer patients was 84% on a per protocol analysis (95% CI: 80%-88%) and 81% on an intention-to-treat analysis (95% CI: 77%-85%), while in the liver cirrhosis patients it was 89% in a per protocol analysis (95% CI: 78%-99%) and 83% in an intention-to-treat analysis (95% CI: 70%-97%).",Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10807427/),%,84,161396,DB00448,Lansoprazole
,10807427,cure rate,"The cure rate for the peptic ulcer patients was 84% on a per protocol analysis (95% CI: 80%-88%) and 81% on an intention-to-treat analysis (95% CI: 77%-85%), while in the liver cirrhosis patients it was 89% in a per protocol analysis (95% CI: 78%-99%) and 83% in an intention-to-treat analysis (95% CI: 70%-97%).",Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10807427/),%,81,161397,DB00448,Lansoprazole
,10807427,cure rate,"The cure rate for the peptic ulcer patients was 84% on a per protocol analysis (95% CI: 80%-88%) and 81% on an intention-to-treat analysis (95% CI: 77%-85%), while in the liver cirrhosis patients it was 89% in a per protocol analysis (95% CI: 78%-99%) and 83% in an intention-to-treat analysis (95% CI: 70%-97%).",Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10807427/),%,89,161398,DB00448,Lansoprazole
,10807427,cure rate,"The cure rate for the peptic ulcer patients was 84% on a per protocol analysis (95% CI: 80%-88%) and 81% on an intention-to-treat analysis (95% CI: 77%-85%), while in the liver cirrhosis patients it was 89% in a per protocol analysis (95% CI: 78%-99%) and 83% in an intention-to-treat analysis (95% CI: 70%-97%).",Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10807427/),%,83,161399,DB00448,Lansoprazole
,20063355,LOQ,The LOQ was established at 1.5 and 5 ng/mL for the two concentration ranges.,A bio-analytical hydrophilic interaction LC-MS/MS method for the simultaneous quantification of omeprazole and lansoprazole in human plasma in support of a pharmacokinetic omeprazole study in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20063355/),[ng] / [ml],1.5,163432,DB00448,Lansoprazole
,20063355,LOQ,The LOQ was established at 1.5 and 5 ng/mL for the two concentration ranges.,A bio-analytical hydrophilic interaction LC-MS/MS method for the simultaneous quantification of omeprazole and lansoprazole in human plasma in support of a pharmacokinetic omeprazole study in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20063355/),[ng] / [ml],5,163433,DB00448,Lansoprazole
,20063355,extraction recovery,"Lack of variability in matrix effects was demonstrated and mean extraction recovery for omeprazole and lansoprazole was determined in the low (56.3-67.7%) and high (45.3-44.3%) concentration range, respectively.",A bio-analytical hydrophilic interaction LC-MS/MS method for the simultaneous quantification of omeprazole and lansoprazole in human plasma in support of a pharmacokinetic omeprazole study in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20063355/),%,56.3-67.7,163434,DB00448,Lansoprazole
,20063355,extraction recovery,"Lack of variability in matrix effects was demonstrated and mean extraction recovery for omeprazole and lansoprazole was determined in the low (56.3-67.7%) and high (45.3-44.3%) concentration range, respectively.",A bio-analytical hydrophilic interaction LC-MS/MS method for the simultaneous quantification of omeprazole and lansoprazole in human plasma in support of a pharmacokinetic omeprazole study in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20063355/),%,45.3-44.3,163435,DB00448,Lansoprazole
,11768559,half-life,"Actually, all PPIs display chemical activation half-lives at pH 1.0 of a few minutes at the most, while being eliminated from serum with a half-life of about 1 h.",Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11768559/),h,1,175782,DB00448,Lansoprazole
,11467632,time to the maximum observed concentration,"Lansoprazole's time to the maximum observed concentration and area under the plasma concentration-time curve over the 24-h time interval increased significantly from day I to day 5 (1.7 h vs 2.0 h and 1865 ng x h/ml vs 2091 ng x h/ml, respectively), and a significant increase in half-life relative to day 1 (0.96 h) was observed on day 5 (1.03 h) during pantoprazole treatment.",Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11467632/),h,1.7,177294,DB00448,Lansoprazole
,11467632,time to the maximum observed concentration,"Lansoprazole's time to the maximum observed concentration and area under the plasma concentration-time curve over the 24-h time interval increased significantly from day I to day 5 (1.7 h vs 2.0 h and 1865 ng x h/ml vs 2091 ng x h/ml, respectively), and a significant increase in half-life relative to day 1 (0.96 h) was observed on day 5 (1.03 h) during pantoprazole treatment.",Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11467632/),h,2.0,177295,DB00448,Lansoprazole
,11467632,area under the plasma concentration-time curve,"Lansoprazole's time to the maximum observed concentration and area under the plasma concentration-time curve over the 24-h time interval increased significantly from day I to day 5 (1.7 h vs 2.0 h and 1865 ng x h/ml vs 2091 ng x h/ml, respectively), and a significant increase in half-life relative to day 1 (0.96 h) was observed on day 5 (1.03 h) during pantoprazole treatment.",Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11467632/),[h·ng] / [ml],1865,177296,DB00448,Lansoprazole
,11467632,area under the plasma concentration-time curve,"Lansoprazole's time to the maximum observed concentration and area under the plasma concentration-time curve over the 24-h time interval increased significantly from day I to day 5 (1.7 h vs 2.0 h and 1865 ng x h/ml vs 2091 ng x h/ml, respectively), and a significant increase in half-life relative to day 1 (0.96 h) was observed on day 5 (1.03 h) during pantoprazole treatment.",Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11467632/),[h·ng] / [ml],2091,177297,DB00448,Lansoprazole
,11467632,half-life,"Lansoprazole's time to the maximum observed concentration and area under the plasma concentration-time curve over the 24-h time interval increased significantly from day I to day 5 (1.7 h vs 2.0 h and 1865 ng x h/ml vs 2091 ng x h/ml, respectively), and a significant increase in half-life relative to day 1 (0.96 h) was observed on day 5 (1.03 h) during pantoprazole treatment.",Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11467632/),h,0.96,177298,DB00448,Lansoprazole
,11467632,half-life,"Lansoprazole's time to the maximum observed concentration and area under the plasma concentration-time curve over the 24-h time interval increased significantly from day I to day 5 (1.7 h vs 2.0 h and 1865 ng x h/ml vs 2091 ng x h/ml, respectively), and a significant increase in half-life relative to day 1 (0.96 h) was observed on day 5 (1.03 h) during pantoprazole treatment.",Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11467632/),h,1.03,177299,DB00448,Lansoprazole
,8803522,total clearance,"The total clearance was 517 ml.min-1, and the absolute bioavailability was 91% for the 30-mg and 81% for the 15-mg enteric-coated formulation.",Pharmacokinetics and absolute bioavailability of lansoprazole. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803522/),[ml] / [min],517,177431,DB00448,Lansoprazole
,8803522,absolute bioavailability,"The total clearance was 517 ml.min-1, and the absolute bioavailability was 91% for the 30-mg and 81% for the 15-mg enteric-coated formulation.",Pharmacokinetics and absolute bioavailability of lansoprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803522/),%,91,177432,DB00448,Lansoprazole
,8803522,absolute bioavailability,"The total clearance was 517 ml.min-1, and the absolute bioavailability was 91% for the 30-mg and 81% for the 15-mg enteric-coated formulation.",Pharmacokinetics and absolute bioavailability of lansoprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803522/),%,81,177433,DB00448,Lansoprazole
,8803522,elimination half-life,The elimination half-life was about 1 h.,Pharmacokinetics and absolute bioavailability of lansoprazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803522/),h,1,177434,DB00448,Lansoprazole
,29403981,flow rate,The flow rate was set at 0.5 mL/min to elute all the analytes and IS within 1.00 min runtime.,"Development and validation of a high throughput UPLC-MS/MS method for simultaneous quantification of esomeprazole, rabeprazole and levosulpiride in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403981/),[ml] / [min],0.5,188171,DB00448,Lansoprazole
,19086331,bioavailability,LODT bioavailability was 76%.,Comparison of the enteral and intravenous lansoprazole pharmacodynamic responses in critically ill patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19086331/),%,76,196890,DB00448,Lansoprazole
,15871633,time to reach maximum plasma concentration,"Like adults, PPIs are rapidly absorbed in children following oral administration; the mean time to reach maximum plasma concentration varies from 1 to 3 hours.",Pharmacokinetics of proton pump inhibitors in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871633/),h,1 to 3,196990,DB00448,Lansoprazole
,15871633,elimination half-lives,"PPIs are rapidly metabolised in children, with short elimination half-lives of around 1 hour, similar to that reported for adults.",Pharmacokinetics of proton pump inhibitors in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871633/),h,1,196991,DB00448,Lansoprazole
,15285851,area under the blood concentration-time curve (AUC0-8),"Coadministration of lansoprazole significantly decreased the oral tacrolimus clearance, resulting in an increase in the area under the blood concentration-time curve (AUC0-8) (control vs with lansoprazole: 29.7 +/- 3.5 vs 44.1 +/- 5.0 ng h mL(-1), P < 0.05).",Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15285851/),[h·ng] / [ml],29.7,198748,DB00448,Lansoprazole
,15285851,area under the blood concentration-time curve (AUC0-8),"Coadministration of lansoprazole significantly decreased the oral tacrolimus clearance, resulting in an increase in the area under the blood concentration-time curve (AUC0-8) (control vs with lansoprazole: 29.7 +/- 3.5 vs 44.1 +/- 5.0 ng h mL(-1), P < 0.05).",Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15285851/),[h·ng] / [ml],44.1,198749,DB00448,Lansoprazole
,21366650,area under the plasma concentration-time curve (AUC(0-12)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[h·ng] / [mg·ml],45·2,204110,DB00448,Lansoprazole
,21366650,area under the plasma concentration-time curve (AUC(0-12)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[h·ng] / [mg·ml],71·0,204111,DB00448,Lansoprazole
,21366650,area under the plasma concentration-time curve (AUC(0-12)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[h·ng] / [mg·ml],74·5,204112,DB00448,Lansoprazole
,21366650,maximum plasma concentration (C(max)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[ng] / [mg·ml],9·3,204113,DB00448,Lansoprazole
,21366650,maximum plasma concentration (C(max)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[h·ng] / [mg·ml],74·5,204114,DB00448,Lansoprazole
,21366650,maximum plasma concentration (C(max)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[h·ng] / [mg·ml],52·4,204115,DB00448,Lansoprazole
,21366650,maximum plasma concentration (C(max)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[ng] / [mg·ml],10·9,204116,DB00448,Lansoprazole
,21366650,maximum plasma concentration (C(max)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[ng] / [mg·ml],6·7,204117,DB00448,Lansoprazole
,10468704,Cmax,"On day 7, Cmax was 1343 ng/mL in patients compared with 765 ng/mL in healthy volunteers, AUC was 3458 ng.h/mL vs. 1350 ng.h/mL and t(1/2) was 1.62 h vs. 0.90 h.",Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10468704/),[ng] / [ml],1343,210072,DB00448,Lansoprazole
,10468704,Cmax,"On day 7, Cmax was 1343 ng/mL in patients compared with 765 ng/mL in healthy volunteers, AUC was 3458 ng.h/mL vs. 1350 ng.h/mL and t(1/2) was 1.62 h vs. 0.90 h.",Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10468704/),[ng] / [ml],765,210073,DB00448,Lansoprazole
,10468704,AUC,"On day 7, Cmax was 1343 ng/mL in patients compared with 765 ng/mL in healthy volunteers, AUC was 3458 ng.h/mL vs. 1350 ng.h/mL and t(1/2) was 1.62 h vs. 0.90 h.",Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10468704/),[h·ng] / [ml],3458,210074,DB00448,Lansoprazole
,10468704,AUC,"On day 7, Cmax was 1343 ng/mL in patients compared with 765 ng/mL in healthy volunteers, AUC was 3458 ng.h/mL vs. 1350 ng.h/mL and t(1/2) was 1.62 h vs. 0.90 h.",Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10468704/),[h·ng] / [ml],1350,210075,DB00448,Lansoprazole
,10468704,t(1/2),"On day 7, Cmax was 1343 ng/mL in patients compared with 765 ng/mL in healthy volunteers, AUC was 3458 ng.h/mL vs. 1350 ng.h/mL and t(1/2) was 1.62 h vs. 0.90 h.",Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10468704/),h,1.62,210076,DB00448,Lansoprazole
,10468704,t(1/2),"On day 7, Cmax was 1343 ng/mL in patients compared with 765 ng/mL in healthy volunteers, AUC was 3458 ng.h/mL vs. 1350 ng.h/mL and t(1/2) was 1.62 h vs. 0.90 h.",Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10468704/),h,0.90,210077,DB00448,Lansoprazole
,16988209,C(max),"Pharmacokinetic parameters for ivabradine did not vary significantly after omeprazole (C(max): 45.0 +/- 36.6 vs 42.7 +/- 27.6 ng/mL, P = .98; AUC: 128 +/- 87 vs 126 +/- 63 ng/mL, P = .82) or lansoprazole administration (C(max): 45.0 +/- 36.6 vs 41.3 +/- 29.4 ng/mL, P = .70; AUC: 128 +/- 87 vs 123 +/- 50, P = .73).","Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988209/),[ng] / [ml],45.0,210682,DB00448,Lansoprazole
,16988209,C(max),"Pharmacokinetic parameters for ivabradine did not vary significantly after omeprazole (C(max): 45.0 +/- 36.6 vs 42.7 +/- 27.6 ng/mL, P = .98; AUC: 128 +/- 87 vs 126 +/- 63 ng/mL, P = .82) or lansoprazole administration (C(max): 45.0 +/- 36.6 vs 41.3 +/- 29.4 ng/mL, P = .70; AUC: 128 +/- 87 vs 123 +/- 50, P = .73).","Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988209/),[ng] / [ml],42.7,210683,DB00448,Lansoprazole
,16988209,AUC,"Pharmacokinetic parameters for ivabradine did not vary significantly after omeprazole (C(max): 45.0 +/- 36.6 vs 42.7 +/- 27.6 ng/mL, P = .98; AUC: 128 +/- 87 vs 126 +/- 63 ng/mL, P = .82) or lansoprazole administration (C(max): 45.0 +/- 36.6 vs 41.3 +/- 29.4 ng/mL, P = .70; AUC: 128 +/- 87 vs 123 +/- 50, P = .73).","Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988209/),[ng] / [ml],128,210684,DB00448,Lansoprazole
,16988209,AUC,"Pharmacokinetic parameters for ivabradine did not vary significantly after omeprazole (C(max): 45.0 +/- 36.6 vs 42.7 +/- 27.6 ng/mL, P = .98; AUC: 128 +/- 87 vs 126 +/- 63 ng/mL, P = .82) or lansoprazole administration (C(max): 45.0 +/- 36.6 vs 41.3 +/- 29.4 ng/mL, P = .70; AUC: 128 +/- 87 vs 123 +/- 50, P = .73).","Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988209/),[ng] / [ml],126,210685,DB00448,Lansoprazole
,16988209,C(max),"Pharmacokinetic parameters for ivabradine did not vary significantly after omeprazole (C(max): 45.0 +/- 36.6 vs 42.7 +/- 27.6 ng/mL, P = .98; AUC: 128 +/- 87 vs 126 +/- 63 ng/mL, P = .82) or lansoprazole administration (C(max): 45.0 +/- 36.6 vs 41.3 +/- 29.4 ng/mL, P = .70; AUC: 128 +/- 87 vs 123 +/- 50, P = .73).","Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988209/),[ng] / [ml],41.3,210686,DB00448,Lansoprazole
,16988209,AUC,"Pharmacokinetic parameters for ivabradine did not vary significantly after omeprazole (C(max): 45.0 +/- 36.6 vs 42.7 +/- 27.6 ng/mL, P = .98; AUC: 128 +/- 87 vs 126 +/- 63 ng/mL, P = .82) or lansoprazole administration (C(max): 45.0 +/- 36.6 vs 41.3 +/- 29.4 ng/mL, P = .70; AUC: 128 +/- 87 vs 123 +/- 50, P = .73).","Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988209/),,128,210687,DB00448,Lansoprazole
,16988209,AUC,"Pharmacokinetic parameters for ivabradine did not vary significantly after omeprazole (C(max): 45.0 +/- 36.6 vs 42.7 +/- 27.6 ng/mL, P = .98; AUC: 128 +/- 87 vs 126 +/- 63 ng/mL, P = .82) or lansoprazole administration (C(max): 45.0 +/- 36.6 vs 41.3 +/- 29.4 ng/mL, P = .70; AUC: 128 +/- 87 vs 123 +/- 50, P = .73).","Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988209/),,123,210688,DB00448,Lansoprazole
,18294109,integrated gastric acidity,"Two-minute administration resulted in a greater percentage of time that the 24-hour pH was above 4 compared with the 30-minute administration (53% vs 47%, p=0.045), with comparable 24-hour integrated gastric acidity (114.4 vs 91.6 mmol*hr/L for 2-min vs 30-min, p=0.335).",Greater immediate gastric acid suppression with lansoprazole 30 mg administered as a 2-minute intravenous bolus injection versus a 30-minute infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294109/),[h·mM] / [l],114.4,215152,DB00448,Lansoprazole
,18294109,integrated gastric acidity,"Two-minute administration resulted in a greater percentage of time that the 24-hour pH was above 4 compared with the 30-minute administration (53% vs 47%, p=0.045), with comparable 24-hour integrated gastric acidity (114.4 vs 91.6 mmol*hr/L for 2-min vs 30-min, p=0.335).",Greater immediate gastric acid suppression with lansoprazole 30 mg administered as a 2-minute intravenous bolus injection versus a 30-minute infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294109/),[h·mM] / [l],91.6,215153,DB00448,Lansoprazole
,22612620,C(max),"After single i.v. doses of 15, 30 and 60 mg LPZ, C(max) and area under the plasma concentration-time curve (AUC(0-t)) of LPZ were 725 ± 151, 1480 ± 190, 3130 ± 480 µg · L(-1) and 1690 ± 1210, 3630 ± 2530, 8080 ± 4550 µg · h · L(-1), respectively.",Pharmacokinetics of lansoprazole and its main metabolites after single intravenous doses in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612620/),[μg] / [l],725,218504,DB00448,Lansoprazole
,22612620,area under the plasma concentration-time curve (AUC(0-t)),"After single i.v. doses of 15, 30 and 60 mg LPZ, C(max) and area under the plasma concentration-time curve (AUC(0-t)) of LPZ were 725 ± 151, 1480 ± 190, 3130 ± 480 µg · L(-1) and 1690 ± 1210, 3630 ± 2530, 8080 ± 4550 µg · h · L(-1), respectively.",Pharmacokinetics of lansoprazole and its main metabolites after single intravenous doses in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612620/),[μg] / [l],3130,218505,DB00448,Lansoprazole
,22612620,area under the plasma concentration-time curve (AUC(0-t)),"After single i.v. doses of 15, 30 and 60 mg LPZ, C(max) and area under the plasma concentration-time curve (AUC(0-t)) of LPZ were 725 ± 151, 1480 ± 190, 3130 ± 480 µg · L(-1) and 1690 ± 1210, 3630 ± 2530, 8080 ± 4550 µg · h · L(-1), respectively.",Pharmacokinetics of lansoprazole and its main metabolites after single intravenous doses in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612620/),[h·μg] / [l],1690,218506,DB00448,Lansoprazole
,22612620,area under the plasma concentration-time curve (AUC(0-t)),"After single i.v. doses of 15, 30 and 60 mg LPZ, C(max) and area under the plasma concentration-time curve (AUC(0-t)) of LPZ were 725 ± 151, 1480 ± 190, 3130 ± 480 µg · L(-1) and 1690 ± 1210, 3630 ± 2530, 8080 ± 4550 µg · h · L(-1), respectively.",Pharmacokinetics of lansoprazole and its main metabolites after single intravenous doses in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612620/),[h·μg] / [l],3630,218507,DB00448,Lansoprazole
,22612620,area under the plasma concentration-time curve (AUC(0-t)),"After single i.v. doses of 15, 30 and 60 mg LPZ, C(max) and area under the plasma concentration-time curve (AUC(0-t)) of LPZ were 725 ± 151, 1480 ± 190, 3130 ± 480 µg · L(-1) and 1690 ± 1210, 3630 ± 2530, 8080 ± 4550 µg · h · L(-1), respectively.",Pharmacokinetics of lansoprazole and its main metabolites after single intravenous doses in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612620/),[h·μg] / [l],8080,218508,DB00448,Lansoprazole
,10743982,time to maximum concentration,"A statistically significant difference was detected in the time to maximum concentration between regimens C and D at 2.1 and 1.5 hours, respectively (P < or = 0.05).",Effect on bioavailability of admixing the contents of lansoprazole capsules with selected soft foods. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10743982/),h,2.1,218903,DB00448,Lansoprazole
,10743982,time to maximum concentration,"A statistically significant difference was detected in the time to maximum concentration between regimens C and D at 2.1 and 1.5 hours, respectively (P < or = 0.05).",Effect on bioavailability of admixing the contents of lansoprazole capsules with selected soft foods. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10743982/),h,1.5,218904,DB00448,Lansoprazole
,16402242,t(1/2 ke),"In the homEMs, hetEMs and PMs, the relative AUC(0-infinity) values were 1:2.8:7.5 for omeprazole, 1:1.7:4.0 for lansoprazole and 1:1.6:3.7 for rabeprazole, respectively; the relative t(1/2 ke) values were 1:1.02:1.65 for omeprazole, 1:1.08:2.39 for lansoprazole and 1:1.37:1.85 for rabeprazole, respectively; the relative c(max) values were 1:2.09:4.39 for omeprazole, 1:1.34:1.72 for lansoprazole, and 1:1.24:2.04 for rabeprazole, respectively.",Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16402242/),,1,224766,DB00448,Lansoprazole
,16402242,t(1/2 ke),"In the homEMs, hetEMs and PMs, the relative AUC(0-infinity) values were 1:2.8:7.5 for omeprazole, 1:1.7:4.0 for lansoprazole and 1:1.6:3.7 for rabeprazole, respectively; the relative t(1/2 ke) values were 1:1.02:1.65 for omeprazole, 1:1.08:2.39 for lansoprazole and 1:1.37:1.85 for rabeprazole, respectively; the relative c(max) values were 1:2.09:4.39 for omeprazole, 1:1.34:1.72 for lansoprazole, and 1:1.24:2.04 for rabeprazole, respectively.",Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16402242/),,1.02,224767,DB00448,Lansoprazole
,16402242,t(1/2 ke),"In the homEMs, hetEMs and PMs, the relative AUC(0-infinity) values were 1:2.8:7.5 for omeprazole, 1:1.7:4.0 for lansoprazole and 1:1.6:3.7 for rabeprazole, respectively; the relative t(1/2 ke) values were 1:1.02:1.65 for omeprazole, 1:1.08:2.39 for lansoprazole and 1:1.37:1.85 for rabeprazole, respectively; the relative c(max) values were 1:2.09:4.39 for omeprazole, 1:1.34:1.72 for lansoprazole, and 1:1.24:2.04 for rabeprazole, respectively.",Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16402242/),,1,224768,DB00448,Lansoprazole
,16402242,t(1/2 ke),"In the homEMs, hetEMs and PMs, the relative AUC(0-infinity) values were 1:2.8:7.5 for omeprazole, 1:1.7:4.0 for lansoprazole and 1:1.6:3.7 for rabeprazole, respectively; the relative t(1/2 ke) values were 1:1.02:1.65 for omeprazole, 1:1.08:2.39 for lansoprazole and 1:1.37:1.85 for rabeprazole, respectively; the relative c(max) values were 1:2.09:4.39 for omeprazole, 1:1.34:1.72 for lansoprazole, and 1:1.24:2.04 for rabeprazole, respectively.",Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16402242/),,1,224769,DB00448,Lansoprazole
,16402242,t(1/2 ke),"In the homEMs, hetEMs and PMs, the relative AUC(0-infinity) values were 1:2.8:7.5 for omeprazole, 1:1.7:4.0 for lansoprazole and 1:1.6:3.7 for rabeprazole, respectively; the relative t(1/2 ke) values were 1:1.02:1.65 for omeprazole, 1:1.08:2.39 for lansoprazole and 1:1.37:1.85 for rabeprazole, respectively; the relative c(max) values were 1:2.09:4.39 for omeprazole, 1:1.34:1.72 for lansoprazole, and 1:1.24:2.04 for rabeprazole, respectively.",Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16402242/),,1.08,224770,DB00448,Lansoprazole
,23806811,solubility,"With a single dose of 30 mg and the solubility of 0.04 mg/ml, the absorption was complete.",Profiling biopharmaceutical deciding properties of absorption of lansoprazole enteric-coated tablets using gastrointestinal simulation technology. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23806811/),[mg] / [ml],0.04,232120,DB00448,Lansoprazole
less,7585848,time elapsed to peak concentration (Tmax),Mean time elapsed to peak concentration (Tmax) was less than 2 hours for each regimen.,Lansoprazole: an alternative method of administration of a capsule dosage formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7585848/),h,2,234243,DB00448,Lansoprazole
,16497565,total time for,"The peak was detected with an ultraviolet detector set at a wavelength of 302 nm, and total time for chromatographic separation was approximately 25 min.",Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotypes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16497565/),min,25,239164,DB00448,Lansoprazole
,16497565,recoveries,"Mean recoveries were 84.3% for omeprazole, 64.3% for 5-hydroxyomeprazole and 86.1% for omeprazole sulfone.",Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotypes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16497565/),%,84.3,239165,DB00448,Lansoprazole
,16497565,recoveries,"Mean recoveries were 84.3% for omeprazole, 64.3% for 5-hydroxyomeprazole and 86.1% for omeprazole sulfone.",Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotypes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16497565/),%,64.3,239166,DB00448,Lansoprazole
,16497565,recoveries,"Mean recoveries were 84.3% for omeprazole, 64.3% for 5-hydroxyomeprazole and 86.1% for omeprazole sulfone.",Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotypes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16497565/),%,86.1,239167,DB00448,Lansoprazole
,11515348,maximum observed plasma concentration (Cmax),The mean maximum observed plasma concentration (Cmax) of the suspension was significantly higher and the mean area under the concentration-time curve from time zero to infinity (AUC infinity) was significantly lower than those of the intact capsule (879 versus 810 ng/mL and 1825 versus 2229 ng.hr/mL).,Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11515348/),[ng] / [ml],879,240307,DB00448,Lansoprazole
,11515348,maximum observed plasma concentration (Cmax),The mean maximum observed plasma concentration (Cmax) of the suspension was significantly higher and the mean area under the concentration-time curve from time zero to infinity (AUC infinity) was significantly lower than those of the intact capsule (879 versus 810 ng/mL and 1825 versus 2229 ng.hr/mL).,Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11515348/),[ng] / [ml],810,240308,DB00448,Lansoprazole
,11515348,area under the concentration-time curve from time zero to infinity (AUC infinity),The mean maximum observed plasma concentration (Cmax) of the suspension was significantly higher and the mean area under the concentration-time curve from time zero to infinity (AUC infinity) was significantly lower than those of the intact capsule (879 versus 810 ng/mL and 1825 versus 2229 ng.hr/mL).,Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11515348/),[h·ng] / [ml],1825,240309,DB00448,Lansoprazole
,11515348,area under the concentration-time curve from time zero to infinity (AUC infinity),The mean maximum observed plasma concentration (Cmax) of the suspension was significantly higher and the mean area under the concentration-time curve from time zero to infinity (AUC infinity) was significantly lower than those of the intact capsule (879 versus 810 ng/mL and 1825 versus 2229 ng.hr/mL).,Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11515348/),[h·ng] / [ml],2229,240310,DB00448,Lansoprazole
,11683127,maximal serum concentrations,"No statistically significant differences, at the probability level of 90%, were observed neither for the maximal serum concentrations (1.12:1.22 micrograms/ml) nor for the area under the concentration-time curves (5.01:5.77 micrograms/ml.h), the parameter to which the inhibition of acid secretion induced by lansoprazole is directly related.",A bioavailability/bioequivalence study of two oral lansoprazole formulations after single administration to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11683127/),[μg] / [ml],1.12,240583,DB00448,Lansoprazole
,11683127,maximal serum concentrations,"No statistically significant differences, at the probability level of 90%, were observed neither for the maximal serum concentrations (1.12:1.22 micrograms/ml) nor for the area under the concentration-time curves (5.01:5.77 micrograms/ml.h), the parameter to which the inhibition of acid secretion induced by lansoprazole is directly related.",A bioavailability/bioequivalence study of two oral lansoprazole formulations after single administration to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11683127/),[μg] / [ml],1.22,240584,DB00448,Lansoprazole
,11683127,area under the concentration-time curves,"No statistically significant differences, at the probability level of 90%, were observed neither for the maximal serum concentrations (1.12:1.22 micrograms/ml) nor for the area under the concentration-time curves (5.01:5.77 micrograms/ml.h), the parameter to which the inhibition of acid secretion induced by lansoprazole is directly related.",A bioavailability/bioequivalence study of two oral lansoprazole formulations after single administration to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11683127/),[μg] / [h·ml],5.01,240585,DB00448,Lansoprazole
,11683127,area under the concentration-time curves,"No statistically significant differences, at the probability level of 90%, were observed neither for the maximal serum concentrations (1.12:1.22 micrograms/ml) nor for the area under the concentration-time curves (5.01:5.77 micrograms/ml.h), the parameter to which the inhibition of acid secretion induced by lansoprazole is directly related.",A bioavailability/bioequivalence study of two oral lansoprazole formulations after single administration to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11683127/),[μg] / [h·ml],5.77,240586,DB00448,Lansoprazole
,11683127,terminal elimination half-lives,The terminal elimination half-lives were 4.56 h for Lasoprol and 4.57 h for the reference formulation.,A bioavailability/bioequivalence study of two oral lansoprazole formulations after single administration to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11683127/),h,4.56,240587,DB00448,Lansoprazole
,11683127,terminal elimination half-lives,The terminal elimination half-lives were 4.56 h for Lasoprol and 4.57 h for the reference formulation.,A bioavailability/bioequivalence study of two oral lansoprazole formulations after single administration to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11683127/),h,4.57,240588,DB00448,Lansoprazole
,21604490,t(1/2),"After receiving single doses of 15, 30 and 60 mg of lansoprazole, t(1/2) were (1.663 +/- 0.405) h, (1.541 +/- 0.339)h and (1.747 +/- 0.156) h; Cmax were (1.065 +/- 0.094) microg/ml, (2.104 +/- 0.312) microg/ml and (3.786 +/- 0.356) microg/ml; AUC(0-infinity) were (2.376 +/- 0. 432) microg x h/ ml, (4.722 +/- 0.753) microg x h/ml and (10.495 +/- 2.129) microg x h/ml respectively.",[Study on pharmacokinetics of lansoprozole in concentration of blood plasma healthy volunteers intravenous infusion by improved HPLC]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21604490/),h,1.663,240993,DB00448,Lansoprazole
,21604490,t(1/2),"After receiving single doses of 15, 30 and 60 mg of lansoprazole, t(1/2) were (1.663 +/- 0.405) h, (1.541 +/- 0.339)h and (1.747 +/- 0.156) h; Cmax were (1.065 +/- 0.094) microg/ml, (2.104 +/- 0.312) microg/ml and (3.786 +/- 0.356) microg/ml; AUC(0-infinity) were (2.376 +/- 0. 432) microg x h/ ml, (4.722 +/- 0.753) microg x h/ml and (10.495 +/- 2.129) microg x h/ml respectively.",[Study on pharmacokinetics of lansoprozole in concentration of blood plasma healthy volunteers intravenous infusion by improved HPLC]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21604490/),h,1.541,240994,DB00448,Lansoprazole
,21604490,t(1/2),"After receiving single doses of 15, 30 and 60 mg of lansoprazole, t(1/2) were (1.663 +/- 0.405) h, (1.541 +/- 0.339)h and (1.747 +/- 0.156) h; Cmax were (1.065 +/- 0.094) microg/ml, (2.104 +/- 0.312) microg/ml and (3.786 +/- 0.356) microg/ml; AUC(0-infinity) were (2.376 +/- 0. 432) microg x h/ ml, (4.722 +/- 0.753) microg x h/ml and (10.495 +/- 2.129) microg x h/ml respectively.",[Study on pharmacokinetics of lansoprozole in concentration of blood plasma healthy volunteers intravenous infusion by improved HPLC]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21604490/),h,1.747,240995,DB00448,Lansoprazole
,21604490,Cmax,"After receiving single doses of 15, 30 and 60 mg of lansoprazole, t(1/2) were (1.663 +/- 0.405) h, (1.541 +/- 0.339)h and (1.747 +/- 0.156) h; Cmax were (1.065 +/- 0.094) microg/ml, (2.104 +/- 0.312) microg/ml and (3.786 +/- 0.356) microg/ml; AUC(0-infinity) were (2.376 +/- 0. 432) microg x h/ ml, (4.722 +/- 0.753) microg x h/ml and (10.495 +/- 2.129) microg x h/ml respectively.",[Study on pharmacokinetics of lansoprozole in concentration of blood plasma healthy volunteers intravenous infusion by improved HPLC]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21604490/),[μg] / [ml],1.065,240996,DB00448,Lansoprazole
,21604490,Cmax,"After receiving single doses of 15, 30 and 60 mg of lansoprazole, t(1/2) were (1.663 +/- 0.405) h, (1.541 +/- 0.339)h and (1.747 +/- 0.156) h; Cmax were (1.065 +/- 0.094) microg/ml, (2.104 +/- 0.312) microg/ml and (3.786 +/- 0.356) microg/ml; AUC(0-infinity) were (2.376 +/- 0. 432) microg x h/ ml, (4.722 +/- 0.753) microg x h/ml and (10.495 +/- 2.129) microg x h/ml respectively.",[Study on pharmacokinetics of lansoprozole in concentration of blood plasma healthy volunteers intravenous infusion by improved HPLC]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21604490/),[μg] / [ml],2.104,240997,DB00448,Lansoprazole
,21604490,Cmax,"After receiving single doses of 15, 30 and 60 mg of lansoprazole, t(1/2) were (1.663 +/- 0.405) h, (1.541 +/- 0.339)h and (1.747 +/- 0.156) h; Cmax were (1.065 +/- 0.094) microg/ml, (2.104 +/- 0.312) microg/ml and (3.786 +/- 0.356) microg/ml; AUC(0-infinity) were (2.376 +/- 0. 432) microg x h/ ml, (4.722 +/- 0.753) microg x h/ml and (10.495 +/- 2.129) microg x h/ml respectively.",[Study on pharmacokinetics of lansoprozole in concentration of blood plasma healthy volunteers intravenous infusion by improved HPLC]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21604490/),[μg] / [ml],3.786,240998,DB00448,Lansoprazole
,21604490,AUC(0-infinity),"After receiving single doses of 15, 30 and 60 mg of lansoprazole, t(1/2) were (1.663 +/- 0.405) h, (1.541 +/- 0.339)h and (1.747 +/- 0.156) h; Cmax were (1.065 +/- 0.094) microg/ml, (2.104 +/- 0.312) microg/ml and (3.786 +/- 0.356) microg/ml; AUC(0-infinity) were (2.376 +/- 0. 432) microg x h/ ml, (4.722 +/- 0.753) microg x h/ml and (10.495 +/- 2.129) microg x h/ml respectively.",[Study on pharmacokinetics of lansoprozole in concentration of blood plasma healthy volunteers intravenous infusion by improved HPLC]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21604490/),[h·μg] / [ml],2.376,240999,DB00448,Lansoprazole
,21604490,AUC(0-infinity),"After receiving single doses of 15, 30 and 60 mg of lansoprazole, t(1/2) were (1.663 +/- 0.405) h, (1.541 +/- 0.339)h and (1.747 +/- 0.156) h; Cmax were (1.065 +/- 0.094) microg/ml, (2.104 +/- 0.312) microg/ml and (3.786 +/- 0.356) microg/ml; AUC(0-infinity) were (2.376 +/- 0. 432) microg x h/ ml, (4.722 +/- 0.753) microg x h/ml and (10.495 +/- 2.129) microg x h/ml respectively.",[Study on pharmacokinetics of lansoprozole in concentration of blood plasma healthy volunteers intravenous infusion by improved HPLC]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21604490/),[h·μg] / [ml],4.722,241000,DB00448,Lansoprazole
,21604490,AUC(0-infinity),"After receiving single doses of 15, 30 and 60 mg of lansoprazole, t(1/2) were (1.663 +/- 0.405) h, (1.541 +/- 0.339)h and (1.747 +/- 0.156) h; Cmax were (1.065 +/- 0.094) microg/ml, (2.104 +/- 0.312) microg/ml and (3.786 +/- 0.356) microg/ml; AUC(0-infinity) were (2.376 +/- 0. 432) microg x h/ ml, (4.722 +/- 0.753) microg x h/ml and (10.495 +/- 2.129) microg x h/ml respectively.",[Study on pharmacokinetics of lansoprozole in concentration of blood plasma healthy volunteers intravenous infusion by improved HPLC]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21604490/),[h·μg] / [ml],10.495,241001,DB00448,Lansoprazole
,12407126,elimination half-life (t(1/2)),"For lansoprazole, the elimination half-life (t(1/2)) was significantly prolonged (1.46 versus 1.7 h, P < 0.05) and the area under the concentration-time curve from 0 to 8 h (AUC(0-8)) was significantly increased (3.65 versus 4.59 mg.h/L, P < 0.05) by combination of the drugs.","Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407126/),h,1.46,243228,DB00448,Lansoprazole
,12407126,elimination half-life (t(1/2)),"For lansoprazole, the elimination half-life (t(1/2)) was significantly prolonged (1.46 versus 1.7 h, P < 0.05) and the area under the concentration-time curve from 0 to 8 h (AUC(0-8)) was significantly increased (3.65 versus 4.59 mg.h/L, P < 0.05) by combination of the drugs.","Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407126/),h,1.7,243229,DB00448,Lansoprazole
,12407126,area under the concentration-time curve from 0 to 8 h (AUC(0-8)),"For lansoprazole, the elimination half-life (t(1/2)) was significantly prolonged (1.46 versus 1.7 h, P < 0.05) and the area under the concentration-time curve from 0 to 8 h (AUC(0-8)) was significantly increased (3.65 versus 4.59 mg.h/L, P < 0.05) by combination of the drugs.","Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407126/),[h·mg] / [l],3.65,243230,DB00448,Lansoprazole
,12407126,area under the concentration-time curve from 0 to 8 h (AUC(0-8)),"For lansoprazole, the elimination half-life (t(1/2)) was significantly prolonged (1.46 versus 1.7 h, P < 0.05) and the area under the concentration-time curve from 0 to 8 h (AUC(0-8)) was significantly increased (3.65 versus 4.59 mg.h/L, P < 0.05) by combination of the drugs.","Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407126/),[h·mg] / [l],4.59,243231,DB00448,Lansoprazole
,12407126,peak concentration (C(max)),"For 14-OH-clarithromycin, the peak concentration (C(max)) was 0.95 versus 1.18 mg/L and the AUC from 0 to 12 h (AUC(0-12)) was 8.3 versus 10.5 mg.h/L (augmented significantly, P < 0.05).","Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407126/),[mg] / [l],0.95,243232,DB00448,Lansoprazole
,12407126,peak concentration (C(max)),"For 14-OH-clarithromycin, the peak concentration (C(max)) was 0.95 versus 1.18 mg/L and the AUC from 0 to 12 h (AUC(0-12)) was 8.3 versus 10.5 mg.h/L (augmented significantly, P < 0.05).","Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407126/),[mg] / [l],1.18,243233,DB00448,Lansoprazole
,12407126,AUC from 0 to 12 h (AUC(0-12)),"For 14-OH-clarithromycin, the peak concentration (C(max)) was 0.95 versus 1.18 mg/L and the AUC from 0 to 12 h (AUC(0-12)) was 8.3 versus 10.5 mg.h/L (augmented significantly, P < 0.05).","Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407126/),[h·mg] / [l],8.3,243234,DB00448,Lansoprazole
,12407126,AUC from 0 to 12 h (AUC(0-12)),"For 14-OH-clarithromycin, the peak concentration (C(max)) was 0.95 versus 1.18 mg/L and the AUC from 0 to 12 h (AUC(0-12)) was 8.3 versus 10.5 mg.h/L (augmented significantly, P < 0.05).","Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407126/),[h·mg] / [l],10.5,243235,DB00448,Lansoprazole
,12407126,time to maximum concentration of drug in serum (T(max)),"For clarithromycin, the time to maximum concentration of drug in serum (T(max)) was increased (2.73 versus 3.31 h, P < 0.05), whereas AUC and C(max) remained unchanged.","Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407126/),h,2.73,243236,DB00448,Lansoprazole
,12407126,time to maximum concentration of drug in serum (T(max)),"For clarithromycin, the time to maximum concentration of drug in serum (T(max)) was increased (2.73 versus 3.31 h, P < 0.05), whereas AUC and C(max) remained unchanged.","Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407126/),h,3.31,243237,DB00448,Lansoprazole
,12959297,AUC,Mean values of AUC after single dose were 2668 ng ml(-1) h in the young subjects and 5216 ng ml(-1) h in the elderly (P < 0.05).,Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959297/),[h·ng] / [ml],2668,246646,DB00448,Lansoprazole
,12959297,AUC,Mean values of AUC after single dose were 2668 ng ml(-1) h in the young subjects and 5216 ng ml(-1) h in the elderly (P < 0.05).,Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959297/),[h·ng] / [ml],5216,246647,DB00448,Lansoprazole
,12959297,t 1/2z,"Mean t 1/2z values in young and elderly subjects were 1.4 h and 2.9 h, respectively (P < 0.001).",Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959297/),h,1.4,246648,DB00448,Lansoprazole
,12959297,t 1/2z,"Mean t 1/2z values in young and elderly subjects were 1.4 h and 2.9 h, respectively (P < 0.001).",Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959297/),h,2.9,246649,DB00448,Lansoprazole
,12959297,accumulation ratio,The accumulation ratio was 1.31 in the elderly subjects.,Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959297/),,1.31,246650,DB00448,Lansoprazole
,9701531,t1/2,The pharmacokinetics of rabeprazole were similar to those of other proton pump inhibitors with a t1/2 of between 0.7 and 1.0 h.,An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9701531/),h,0.7 and 1.0,250659,DB00448,Lansoprazole
,1400730,quantification,The quantification limit was 2 ng/ml for lansoprazole and 3 or 5 ng/ml for the metabolites.,Determination of lansoprazole and its metabolites in plasma by high-performance liquid chromatography using a loop column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400730/),[ng] / [ml],2,252285,DB00448,Lansoprazole
,1400730,quantification,The quantification limit was 2 ng/ml for lansoprazole and 3 or 5 ng/ml for the metabolites.,Determination of lansoprazole and its metabolites in plasma by high-performance liquid chromatography using a loop column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400730/),[ng] / [ml],3,252286,DB00448,Lansoprazole
,1400730,quantification,The quantification limit was 2 ng/ml for lansoprazole and 3 or 5 ng/ml for the metabolites.,Determination of lansoprazole and its metabolites in plasma by high-performance liquid chromatography using a loop column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400730/),[ng] / [ml],5,252287,DB00448,Lansoprazole
,1400730,overall recovery,The mean overall recovery was between 75 and 95% for lansoprazole and its metabolites.,Determination of lansoprazole and its metabolites in plasma by high-performance liquid chromatography using a loop column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400730/),%,75 and 95,252288,DB00448,Lansoprazole
,20456825,flow rate,"Following a single step liquid-liquid extraction analytes along with an internal standard (IS) were separated using an isocratic mobile phase of phosphate buffer (10 mM)/acetonitrile (53/47, v/v adjusted pH to 7.3 with triethylamine) at flow rate of 1 mL/min on reverse phase TRACER EXCEL 120 ODS-A column at room temperature.","Improved HPLC method for determination of four PPIs, omeprazole, pantoprazole, lansoprazole and rabeprazole in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20456825/),[ml] / [min],1,253824,DB00448,Lansoprazole
,20456825,Total analytical run time,Total analytical run time for selected PPIs was 10 min.,"Improved HPLC method for determination of four PPIs, omeprazole, pantoprazole, lansoprazole and rabeprazole in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20456825/),min,10,253825,DB00448,Lansoprazole
greater,20456825,recovery of,The recovery of method was equal or greater than 80% and lower limit of quantification (LLOQ) was 20 ng/mL for four PPIs.,"Improved HPLC method for determination of four PPIs, omeprazole, pantoprazole, lansoprazole and rabeprazole in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20456825/),%,80,253826,DB00448,Lansoprazole
,15548851,AUC(0-24s),The mean AUC(0-24s) were 2004.4+/-973.6 ng.h/mL in without-water experiment and 2018.5+/-1159.6 ng.h/mL in the case of with-water experiment.,Effect of water intake on pharmacokinetics of lansoprazole from fast disintegrating tablet in human subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15548851/),[h·ng] / [ml],2004.4,255420,DB00448,Lansoprazole
,15548851,AUC(0-24s),The mean AUC(0-24s) were 2004.4+/-973.6 ng.h/mL in without-water experiment and 2018.5+/-1159.6 ng.h/mL in the case of with-water experiment.,Effect of water intake on pharmacokinetics of lansoprazole from fast disintegrating tablet in human subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15548851/),[h·ng] / [ml],2018.5,255421,DB00448,Lansoprazole
,15548851,C(maxs),"Mean C(maxs) were 851.9+/-450.8 ng/mL in without-water experiment and 830.8+/-456.8 ng/mL in with-water experiment, respectively.",Effect of water intake on pharmacokinetics of lansoprazole from fast disintegrating tablet in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15548851/),[ng] / [ml],851.9,255422,DB00448,Lansoprazole
,15548851,C(maxs),"Mean C(maxs) were 851.9+/-450.8 ng/mL in without-water experiment and 830.8+/-456.8 ng/mL in with-water experiment, respectively.",Effect of water intake on pharmacokinetics of lansoprazole from fast disintegrating tablet in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15548851/),[ng] / [ml],830.8,255423,DB00448,Lansoprazole
,25145453,time to maximum plasma concentration (t max),Lansoprazole coadministration resulted in a 1-h increase in the time to maximum plasma concentration (t max) of ponatinib (6 vs. 5 h post-dose; P < 0.001).,Evaluation of the effect of multiple doses of lansoprazole on the pharmacokinetics and safety of ponatinib in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25145453/),h,6,255570,DB00448,Lansoprazole
,25145453,time to maximum plasma concentration (t max),Lansoprazole coadministration resulted in a 1-h increase in the time to maximum plasma concentration (t max) of ponatinib (6 vs. 5 h post-dose; P < 0.001).,Evaluation of the effect of multiple doses of lansoprazole on the pharmacokinetics and safety of ponatinib in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25145453/),h,5,255571,DB00448,Lansoprazole
,25145453,maximum plasma concentration (C max),A corresponding 25 % decrease in the geometric mean maximum plasma concentration (C max) of ponatinib was observed for ponatinib + lansoprazole versus ponatinib alone (40.67 vs. 53.96 ng/mL).,Evaluation of the effect of multiple doses of lansoprazole on the pharmacokinetics and safety of ponatinib in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25145453/),[ng] / [ml],40.67,255572,DB00448,Lansoprazole
,25145453,maximum plasma concentration (C max),A corresponding 25 % decrease in the geometric mean maximum plasma concentration (C max) of ponatinib was observed for ponatinib + lansoprazole versus ponatinib alone (40.67 vs. 53.96 ng/mL).,Evaluation of the effect of multiple doses of lansoprazole on the pharmacokinetics and safety of ponatinib in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25145453/),[ng] / [ml],53.96,255573,DB00448,Lansoprazole
,25145453,area under the plasma concentration-time curve from time zero to infinity (AUC∞,"Importantly, lansoprazole did not decrease the overall ponatinib systemic exposure as assessed by the ponatinib area under the plasma concentration-time curve from time zero to infinity (AUC∞ 1,153 ng·h/mL for lansoprazole + ponatinib vs. 1,222 ng·h/mL for ponatinib alone).",Evaluation of the effect of multiple doses of lansoprazole on the pharmacokinetics and safety of ponatinib in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25145453/),[h·ng] / [ml],"1,153",255574,DB00448,Lansoprazole
,25145453,area under the plasma concentration-time curve from time zero to infinity (AUC∞,"Importantly, lansoprazole did not decrease the overall ponatinib systemic exposure as assessed by the ponatinib area under the plasma concentration-time curve from time zero to infinity (AUC∞ 1,153 ng·h/mL for lansoprazole + ponatinib vs. 1,222 ng·h/mL for ponatinib alone).",Evaluation of the effect of multiple doses of lansoprazole on the pharmacokinetics and safety of ponatinib in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25145453/),[h·ng] / [ml],"1,222",255575,DB00448,Lansoprazole
,21716130,Cmax,"Cmax (691 and 1136 ng/mL) and area under the plasma concentration time curve (2886 and 5120 ng · h/mL) values for the 30- and 60-mg doses, respectively, were similar to results from previous phase 1 studies in healthy adults.",Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21716130/),[ng] / [ml],691,258620,DB00448,Lansoprazole
,21716130,Cmax,"Cmax (691 and 1136 ng/mL) and area under the plasma concentration time curve (2886 and 5120 ng · h/mL) values for the 30- and 60-mg doses, respectively, were similar to results from previous phase 1 studies in healthy adults.",Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21716130/),[ng] / [ml],1136,258621,DB00448,Lansoprazole
,21716130,area under the plasma concentration time curve,"Cmax (691 and 1136 ng/mL) and area under the plasma concentration time curve (2886 and 5120 ng · h/mL) values for the 30- and 60-mg doses, respectively, were similar to results from previous phase 1 studies in healthy adults.",Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21716130/),[h·ng] / [ml],2886,258622,DB00448,Lansoprazole
,21716130,area under the plasma concentration time curve,"Cmax (691 and 1136 ng/mL) and area under the plasma concentration time curve (2886 and 5120 ng · h/mL) values for the 30- and 60-mg doses, respectively, were similar to results from previous phase 1 studies in healthy adults.",Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21716130/),[h·ng] / [ml],5120,258623,DB00448,Lansoprazole
,32671657,IC50,"In vitro studies demonstrated that PPIs inhibited rOAT3-mediated uptake of MTX, with estimated IC50 values of 2.1-5.2 μM, and a rank order of esomeprazole ≈ lansoprazole ≈ omeprazole > rabeprazole.",Evaluation of possible pharmacokinetic interaction between methotrexate and proton pump inhibitors in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32671657/),μM,2.1-5.2,258778,DB00448,Lansoprazole
,21877765,maximum plasma concentration (C(max)),"In the two periods of treatment, the mean maximum plasma concentration (C(max)) values were 817 ng/mL (lansoprazole alone) and 1370 ng/mL (lansoprazole in combination with fluoxetine after pre-treatment with fluoxetine for 8 days) [p < 0.0001].",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),[ng] / [ml],817,260422,DB00448,Lansoprazole
,21877765,maximum plasma concentration (C(max)),"In the two periods of treatment, the mean maximum plasma concentration (C(max)) values were 817 ng/mL (lansoprazole alone) and 1370 ng/mL (lansoprazole in combination with fluoxetine after pre-treatment with fluoxetine for 8 days) [p < 0.0001].",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),[ng] / [ml],1370,260423,DB00448,Lansoprazole
,21877765,area under the plasma concentration-time curve (AUC) from time zero to time of last measurable concentration,"The observed area under the plasma concentration-time curve (AUC) from time zero to time of last measurable concentration values were 2400 and 6220 ng · h/mL (p < 0.0001), respectively, and the AUC from time zero to infinity values were 2480 and 7290 ng · h/mL (p < 0.0001), respectively.",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),[h·ng] / [ml],2400,260424,DB00448,Lansoprazole
,21877765,area under the plasma concentration-time curve (AUC) from time zero to time of last measurable concentration,"The observed area under the plasma concentration-time curve (AUC) from time zero to time of last measurable concentration values were 2400 and 6220 ng · h/mL (p < 0.0001), respectively, and the AUC from time zero to infinity values were 2480 and 7290 ng · h/mL (p < 0.0001), respectively.",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),[h·ng] / [ml],6220,260425,DB00448,Lansoprazole
,21877765,AUC from time zero to infinity,"The observed area under the plasma concentration-time curve (AUC) from time zero to time of last measurable concentration values were 2400 and 6220 ng · h/mL (p < 0.0001), respectively, and the AUC from time zero to infinity values were 2480 and 7290 ng · h/mL (p < 0.0001), respectively.",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),[h·ng] / [ml],2480,260426,DB00448,Lansoprazole
,21877765,AUC from time zero to infinity,"The observed area under the plasma concentration-time curve (AUC) from time zero to time of last measurable concentration values were 2400 and 6220 ng · h/mL (p < 0.0001), respectively, and the AUC from time zero to infinity values were 2480 and 7290 ng · h/mL (p < 0.0001), respectively.",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),[h·ng] / [ml],7290,260427,DB00448,Lansoprazole
,21877765,time to reach C(max),"The time to reach C(max) values were 2.72 and 2.64 hours, respectively.",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),h,2.72,260428,DB00448,Lansoprazole
,21877765,time to reach C(max),"The time to reach C(max) values were 2.72 and 2.64 hours, respectively.",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),h,2.64,260429,DB00448,Lansoprazole
,21877765,elimination rate constant from the central compartment,"The elimination rate constant from the central compartment values were 0.50 and 0.21 h-1, respectively (p < 0.0001).",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),1/[h],0.50,260430,DB00448,Lansoprazole
,21877765,elimination rate constant from the central compartment,"The elimination rate constant from the central compartment values were 0.50 and 0.21 h-1, respectively (p < 0.0001).",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),1/[h],0.21,260431,DB00448,Lansoprazole
,21877765,elimination half-life,"The elimination half-life values were 1.47 and 3.56 hours (p < 0.0001), respectively, and the mean residence times were 4.0 and 6.9 hours (p < 0.0001), respectively.",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),h,1.47,260432,DB00448,Lansoprazole
,21877765,elimination half-life,"The elimination half-life values were 1.47 and 3.56 hours (p < 0.0001), respectively, and the mean residence times were 4.0 and 6.9 hours (p < 0.0001), respectively.",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),h,3.56,260433,DB00448,Lansoprazole
,21877765,mean residence times,"The elimination half-life values were 1.47 and 3.56 hours (p < 0.0001), respectively, and the mean residence times were 4.0 and 6.9 hours (p < 0.0001), respectively.",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),h,4.0,260434,DB00448,Lansoprazole
,21877765,mean residence times,"The elimination half-life values were 1.47 and 3.56 hours (p < 0.0001), respectively, and the mean residence times were 4.0 and 6.9 hours (p < 0.0001), respectively.",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),h,6.9,260435,DB00448,Lansoprazole
,19360758,flow rate,"The baseline separation of all the peaks was achieved with 0.1% triethylamine (pH 6.0):acetonitrile (72:28, v/v) at a flow rate of 1 mL/min on a Zorbax C(8) column.","Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19360758/),[ml] / [min],1,262031,DB00448,Lansoprazole
,19360758,total chromatographic run time,"The total chromatographic run time was 11.0 min and the simultaneous elution of IS, OPZ, RPZ, PPZ and LPZ occurred at approximately 2.42, 4.45, 5.02 and 9.37 min, respectively.","Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19360758/),min,11.0,262032,DB00448,Lansoprazole
,19360758,total chromatographic run time,"The total chromatographic run time was 11.0 min and the simultaneous elution of IS, OPZ, RPZ, PPZ and LPZ occurred at approximately 2.42, 4.45, 5.02 and 9.37 min, respectively.","Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19360758/),min,2.42,262033,DB00448,Lansoprazole
,19360758,total chromatographic run time,"The total chromatographic run time was 11.0 min and the simultaneous elution of IS, OPZ, RPZ, PPZ and LPZ occurred at approximately 2.42, 4.45, 5.02 and 9.37 min, respectively.","Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19360758/),min,5.02,262034,DB00448,Lansoprazole
,33425456,flow-rate,"The enantioseparation was achieved on a CHIRALPAK AS-RH column (4.6 mm × 150 mm, i.d. 5 μm), with a mobile phase composed of 10 mM ammonium acetate aqueous solution and acetonitrile (60:40, V/V), at a flow-rate of 0.5 mL/min.",Development of a UHPLC-MS/MS method for the quantification of ilaprazole enantiomers in rat plasma and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33425456/),[ml] / [min],0.5,264611,DB00448,Lansoprazole
,17358097,area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)),"The mean area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)) of (R)- and (S)-lansoprazole in recipients with the CYP3A5*1 allele were 3145 and 384 ng * h/mL, respectively, compared with 4218 and 587 ng * h/mL in recipients with the CYP3A5*3/*3 genotype.",Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17358097/),[h·ng] / [ml],3145,266003,DB00448,Lansoprazole
,17358097,area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)),"The mean area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)) of (R)- and (S)-lansoprazole in recipients with the CYP3A5*1 allele were 3145 and 384 ng * h/mL, respectively, compared with 4218 and 587 ng * h/mL in recipients with the CYP3A5*3/*3 genotype.",Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17358097/),[h·ng] / [ml],384,266004,DB00448,Lansoprazole
,17358097,area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)),"The mean area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)) of (R)- and (S)-lansoprazole in recipients with the CYP3A5*1 allele were 3145 and 384 ng * h/mL, respectively, compared with 4218 and 587 ng * h/mL in recipients with the CYP3A5*3/*3 genotype.",Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17358097/),[h·ng] / [ml],4218,266005,DB00448,Lansoprazole
,17358097,area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)),"The mean area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)) of (R)- and (S)-lansoprazole in recipients with the CYP3A5*1 allele were 3145 and 384 ng * h/mL, respectively, compared with 4218 and 587 ng * h/mL in recipients with the CYP3A5*3/*3 genotype.",Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17358097/),[h·ng] / [ml],587,266006,DB00448,Lansoprazole
,17358097,R/S ratio,The mean R/S ratio for AUC of lansoprazole in each CYP3A5 genotype group was the same (12.6).,Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17358097/),,12.6,266007,DB00448,Lansoprazole
,1424419,plasma elimination half-life,"During the placebo session, the plasma elimination half-life, clearance, and volume of distribution of diazepam were 26.0 +/- 1.6 hours, 22.5 +/- 1.1 ml/hr/kg, and 0.82 +/- 0.04 L/kg, respectively.",Influence of lansoprazole treatment on diazepam plasma concentrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424419/),h,26.0,268808,DB00448,Lansoprazole
,1424419,clearance,"During the placebo session, the plasma elimination half-life, clearance, and volume of distribution of diazepam were 26.0 +/- 1.6 hours, 22.5 +/- 1.1 ml/hr/kg, and 0.82 +/- 0.04 L/kg, respectively.",Influence of lansoprazole treatment on diazepam plasma concentrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424419/),[ml] / [h·kg],22.5,268809,DB00448,Lansoprazole
,1424419,volume of distribution,"During the placebo session, the plasma elimination half-life, clearance, and volume of distribution of diazepam were 26.0 +/- 1.6 hours, 22.5 +/- 1.1 ml/hr/kg, and 0.82 +/- 0.04 L/kg, respectively.",Influence of lansoprazole treatment on diazepam plasma concentrations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424419/),[l] / [kg],0.82,268810,DB00448,Lansoprazole
greater,1810958,recoveries,"The recoveries of authentic analytes added to serum at 0.05-2 micrograms/ml or to urine at 1-20 micrograms/ml were greater than 88%, with the coefficients of variation less than 7.1%.",High-performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810958/),,88,269128,DB00448,Lansoprazole
,1810958,minimum determinable concentrations,The minimum determinable concentrations of all analytes were 5 ng/ml in serum and 50 ng/ml in urine.,High-performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810958/),[ng] / [ml],5,269129,DB00448,Lansoprazole
,1810958,minimum determinable concentrations,The minimum determinable concentrations of all analytes were 5 ng/ml in serum and 50 ng/ml in urine.,High-performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810958/),[ng] / [ml],50,269130,DB00448,Lansoprazole
,23350044,elimination half-life,PPIs have about 1hour of elimination half-life.,Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23350044/),h,1,271438,DB00448,Lansoprazole
,15499190,C(max),The mean C(max) and AUC(0-24) were 474.1+/-254.0 ng/mL and 1105.3+/-1101.4 ng.h/mL (15 mg) and 992.8+/-384.3 ng/mL and 2216.5+/-1270.1 ng.h/mL (30 mg).,Evaluation of fast disintegrating lansoprazole tablet in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15499190/),[ng] / [ml],474.1,271451,DB00448,Lansoprazole
,15499190,C(max),The mean C(max) and AUC(0-24) were 474.1+/-254.0 ng/mL and 1105.3+/-1101.4 ng.h/mL (15 mg) and 992.8+/-384.3 ng/mL and 2216.5+/-1270.1 ng.h/mL (30 mg).,Evaluation of fast disintegrating lansoprazole tablet in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15499190/),[ng] / [ml],992.8,271452,DB00448,Lansoprazole
,15499190,AUC(0-24),The mean C(max) and AUC(0-24) were 474.1+/-254.0 ng/mL and 1105.3+/-1101.4 ng.h/mL (15 mg) and 992.8+/-384.3 ng/mL and 2216.5+/-1270.1 ng.h/mL (30 mg).,Evaluation of fast disintegrating lansoprazole tablet in human subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15499190/),[h·ng] / [ml],1105.3,271453,DB00448,Lansoprazole
,15499190,AUC(0-24),The mean C(max) and AUC(0-24) were 474.1+/-254.0 ng/mL and 1105.3+/-1101.4 ng.h/mL (15 mg) and 992.8+/-384.3 ng/mL and 2216.5+/-1270.1 ng.h/mL (30 mg).,Evaluation of fast disintegrating lansoprazole tablet in human subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15499190/),[h·ng] / [ml],2216.5,271454,DB00448,Lansoprazole
